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Abstract 
Kinetic limitations associated with heterogeneous phase reaction for micron size catalyst 
formulations so far have been addressed by bottom-up approach, which while successful 
through a number of methods tends to involve laborious procedures, high production costs 
and is restricted to a limited number of proteins. 
This study presents the top-down approach, based on physical downsizing of conveniently 
fabricated crosslinked protein aggregates (CLPA) or herein developed crosslinked protein 
lyophilizates (CLPL). This method, while retaining both process convenience/generality 
and stability advantages associated with crosslinking of CLPA leads to nano-particle 
formulations of adjustable size, applicable on a wide range of proteins, independent of their 
purity grade. 
Crosslinked protein micron-sized aggregates were prepared by crash precipitation of 
soluble proteins, alternatively lyophilizates were prepared. The solid proteins were 
chemically or dehydrothermally crosslinked, forming insoluble powders. The crosslinked 
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precursors were then nanonized, realized through application of mechanical or 
hydrodynamic shear, facilitated by an optimal medium. 
Herein, conventional CLPA synthesis was optimized as to facilitate subsequent downsizing. 
Alternative CLPA/CLPL formulations were also developed, addressing challenges posed 
by particular protein types, addressing suboptimal overall synthesis yields and/or catalytic 
activity. Various parameters, such as precursor crosslinked material properties, shear rate 
and time and downsizing medium composition were employed in nanonization procedure 
optimization. Catalytically active nano-particles on the range of 100-900 nm were 
generated.   
The nanonized aggregates described herein serve to highlight a number of potential 
advantages in industrial, analytical and biomedical fields. A preliminary in vitro study 
showed succesful internalization of nanosized CLPAs in different mammalian cell cultures 
in the formulation dependant manner, raising hopes for novel systemic and local protein-
based therapeutics.  
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Özet 
Şimdiye kadar, mikron boyutta katalizör formülasyon durumundaki heterojen faz 
tepkimeler ile alakalı kinetik sınırlanmalar aşağıdan-yukarı yaklaşımıyla ele alınmıştır. Bu 
yaklaşım, mevcut bir takım yöntemlerle başarılı olup, zahmetli prosedürler, yüksek üretim 
maliyeti ve sınırlı sayıda protein için uygulanabiliriği gibi dezavantajlara sahiptir.     
Bu çalışma ilk yukarıdan-aşağı yaklaşımı öne sürmekte ve kolay üretilebilir bilinen çapraz 
bağlı protein agregatların (CLPA) veya bu çalışma kapsamında geliştirilmiş çapraz bağlı 
protein liyofilizatların (CLPL) fiziksel olarak boyut ufaltma yöntemine dayanmaktadır. Bu 
yöntem, CLPA/CLPL'ya özgün çapraz bağlamadan kaynaklanan stabilite, üretim kolaylığı 
ve genel uygulanabilirlik avantajlarını koruyarak, boyutu ayarlanabilir nano-parçacık 
oluşumuna yol açmaktadır ve yüksek çeşitlilikte protein türü üzerinde, saflık derecelerinden 
bağımsız olarak, uygulanabilmektedir.    
Mikron boyutta çapraz bağlı protein agregatlar çözünen proteinlerden ani çöktürme ile 
veya, alternatif olarak, liyofilizasyon yöntemiyle hazırlanmıştır. Oluşan katı formda 
proteinler, çözünmez tozlar oluşturmak üzere, kimyasal veya dehidrotermal olarak çapraz 
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bağlanmıştır. Bunun ardından, çapraz bağlı bu ön-malzemeler, uygun ortam içerisinde 
mekanik veya hidrodinamik makaslama gerilimi uygulanarak nanoboyuta indirgenmiştir. 
Çalışma kapsamında, boyut ufaltma sürecini kolaylaştırmak amacıyla bilinen CLPA üretim 
yöntemleri optimize edilmiştir. 
Bunun dışında, belirli protein türlerine özgün üretim verimi ve/veya katalitik aktivite 
sorunlarını gidermek amacıyla, alternatif CLPA/CLPL formülasyonları geliştirilmiştir. 
Nanonizasyon süreci optimizasyonu, çapraz bağlı ön-malzeme özellikleri, makaslama 
gerilim hızı ve süresi ve nanonizasyon ortamı gibi parametreler kullanılarak 
gerçekleştirilmiştir. 
100-900 nm boyut aralığında katalitik olarak aktif nano-parçacıklar üretilmiştir. 
Bahsi geçen nanonize edilmiş agregatlar, endüstiyel, analitik ve biyomedikal alanlarda  
çeşitli potansiyel avantajlara sahiptir. Öncü in vitro çalışması, malzeme formülasyonuna 
bağlı olarak, nano-CLPA/CLPL'ların farklı memeli hücre kültürlerinde hücre tarafından 
başarılı  bir şekilde alınımı gösterilmiştir. Bu sonuç potansiyel yeni sistemik ve lokal 
protein bazlı ilaç formülasyonların geliştirilmesine ümit vermektedir. 
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1. Introduction 
 
 
 
 
1.1. Protein Immobilization Formulations 
 
 
 
1.1.1. Protein immobilization rationale 
 
 
Various protein-based formulations are being routinely used in a wide range of industrial, 
analytical and biomedical fields
1
. The general goal of various immobilization techniques 
developed over years is to overcome drawbacks of free enzymes as materials such as, low 
stability under various conditions prescribed by the nature of a given application, short 
shelf life and lack of reusability
2,3
. In the particular case of drug delivery formulations, 
reduced bioavailability by enzymatic degradation or renal filtration, and low cellular uptake 
efficiency and specificity are crucial points of interest, which merit constant improvement. 
The existing approaches to immobilization can be generally categorized as physical 
adsorption, encapsulation, surface immobilization and crosslinking
4,5
. The later involves 
covalent bonding of protein alone, or aided by grafting with supplementary protein and/or 
other organic polymer, and forms the technique of interest in this study falls into the latter 
category. 
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1.1.2. Crosslinking 
 
 
Crosslinking is the process of chemically joining two or more molecules by a covalent 
bond. Covalent modification and crosslinking of proteins is facilitated through chemical 
reagent capable of reacting with the specific functional groups naturally present in proteins 
structure. These groups are constituted of protein amino acid side chains, namely are 
amino-, carboxy-  and sulfhydril (Figure 1.1).  
 
Figure 1.1: Protein functional groups at physiological pH 
 
Sulfhydril group modification is a widely used method especially where more specific 
modification modes are required, but will not be further discussed herein
6
 
The charged amino acid side chains are generally more abundantly located at the inferior of 
a globular protein, rendering them a susceptible target for intermolecular conjugation. 
Modification oriented at these functional groups is not specific and mentioned location 
relatively protects resultant conjugates from dramatic conformational alterations. That 
being said, improperly-chosen or sub-optimally utilized crosslinkers could knock-out 
residues important to binding or catalysis without altering the protein global structure, 
yielding an apparent reduction of overall activity
7
. 
Primary amines are present at the N-terminus of a polypeptide chain (α-amine) and in the 
side chain of lysine (Lys) residues (ε-amine). These are subject to modification with N-
hydroxy succinmide esters, imidoesters and aldehydes. For the purposes of inter-protein 
conjugation, bifunctional crosslinking reagents are employed. Aldehyde functional 
crosslinking reagents were utilized in this study. 
3 
 
Formaldehyde and glutaraldehyde are one of the most abundantly used crosslinking reagent 
intended for various applications
8
. These are also highly toxic and due to small molecular 
size can readily penetrate the protein interior and lead to extensive modifications directly 
affecting areas responsible for catalyst or binding, leading to permanent degradation of 
catalytic activity. Larger molecular weight alternatives have been preferred in protein 
modification, due to decreased toxicity and higher specificity towards surface modification. 
The aldehyde alternative of choice in this study is dextran polyaldehyde, conventionally 
applied in biomedical applications due its relatively low toxicity
9
.The reaction mechanism 
of aldehydes with amino residues is demonstrated briefly on Figure 1.2.  
The dehydration upon formation of Schiff bases intermediate is reversible and reduction 
with sodium cyanoborohydride or sodium borohydride is necessary under most reaction 
conditions. Sodium cyanoborohydride is widely used where milder reduction conditions, 
but is highly toxic. More reactive sodium borohydride has been used throughout this study. 
The mechanism illustrated herein is very simplified, in reality glutaraldehyde species in 
aqueous solutions greatly vary, undergoing aldol condensation to form unsaturated 
polyaldehyde species.  Furthermore, different proposed reaction mechanisms are likely to 
contribute the overall product crosslinking, particularly varying with pH of glutaraldehyde 
solution with relation to dominating aqueous species
10,11
. 
 
 
Figure 1.2: Reaction of amino functionalized species with bifunctional aldehyde 
 
Carboxylic functional (–COOH) residues are present at the C-terminus of a polypeptide 
chain and in the side chains of aspartic acid (Asp) and glutamic acid (Glu). Carboxyls are 
reactive towards carboiimides
7
. On the contrary to the described reactions incorporation of 
carbodiimide reagents leads to zero-length amide bond formation between the reagent 
activated carboxyl residue and a juxtaposed amino group (Figure 1.3). This method is 
widely applied in peptide synthesis, but low efficiency is expected upon diffusion 
4 
 
challenged large substrates, due to instability of activated O–acylisourea intermediate. 
Incorporation of N-hydroxysuccinimide or its analogues stabilizes the carboxyl 
intermediate, therefore increasing the possible time frame of the potential conjugation.      
 
 
Figure 1.3: Reaction of carbodiimides through carboxyl group activation of peptide 
carboxyl residues, with subsequent amino residue conjugation    
 
Protein structure and function are closely interconnected, and any possible alterations 
induced by reagent modification must be taken into account. While non specific 
crosslinking of proteins in aqueous solution is widely applied, it often isn’t optimal and 
leads to dramatic catalytic activity loss. This issue has been very successfully addressed by 
introduction of crosslinked protein crystals and aggregates.  
 
 
 
1.2. Crosslinked Protein Crystals (CLPC) and Aggregates (CLPA) 
 
 
 
Out of conventional crosslinked enzyme formulations, Crosslinked Enzyme Crystals 
(CLEC), developed by Quiocho et. al.
12
 in 1964, formed and remained the most efficient 
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example in terms of stability and catalytic performance. Technique was initially developed 
in an attempt to obtain a stable enzyme crystal formulation for X-ray diffraction studies. 
During this study it has become apparent that such formulations retained biocatalytic 
activity, while gaining greatly enhanced mechanical, chemical and thermal stability. 
Nevertheless, further development of the technique aiming enhanced biocatalyst 
formulations has not been improved significantly until last two decades, when Vertex 
Pharmaceuticals have rendered this catalyst commercially available, for a number of 
proteins
13
. 
CLEC provide a very stable formulation with advantage of very pure enzyme content, 
which implies high catalyst to weight ratio
14-17
.  That being said, formulations involve a 
very laborious synthesis process, requires only enzymes of very high purity, and results in 
low yields, which also implies very high costs of large scale productions. This technique is 
limited to only certain (crystallizable) enzymes.  
Addressing most of the described drawbacks, crosslinked enzyme aggregate technology has 
been pioneered by Roger Sheldon et. al. CLEA retain very good stability while based on a 
very general user friendly synthesis process which can also be applied to a very wide range 
of proteins
18,19
  
The principle of the technique lies within stabilization of proteins in form of aggregates, 
achieved by crash precipitation. Apparently, the tertiary structural alteration of proteins 
sterically locked in the relatively rigid aggregate state is prevented throughout the course of 
chemical modification, resulting in rather robust catalytically active material
20
. 
Furthermore, aggregation process serves as a purification step, and is applicable on 
industrial grade proteins. 
The increase in catalytic activity observed in various CLEC and CLEA formulations could 
be rationalized through neighbor- and crosslinker-induced restrictions of conformational 
freedom, which would reduce the protein’s entropy per unit time. The end result would be 
Gibbs ground state elevation of individual proteins in the CLPA, yielding more reactive 
catalysts. While potentially degrading effect of a crosslinking reagent cannot be dismissed, 
in the optimized formulations it does not appear to dominate. 
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1.3. Goal of This Study: nano-CLPA  
 
 
 
The topic of this study has been inspired by the described CLEC and CLPA materials.  
The micron and greater size catalyst introduces an assortment of problems foreign to 
individual proteins, such as mass transport limitations, reduced access to catalytic centers, 
restricted catalytic turnover due to crosslinking, and poor bioabsorptivity
21
  
When considering solid state catalyst systems it should be noted that Michaelis-Menten 
analysis only yields apparent values, due to heterogeneous reaction environment. The 
reaction rate is limited by mass transport and diffusion, reduced access to catalytic centers 
and restricted catalytic turnover due to crosslinking. Heterogeneous size distribution of 
particles also leads to unpredictable/poorly reproducible reaction rates. The particle size is 
particularly important in the case of biomedical applications, which imply cellular 
internalization. These require very well defined nano-scale particles, depending on the 
aimed behavior
22
. 
As described earlier, while forming a golden standard of immobilized protein formulations 
CLECs synthesis is very laborious and resultant particle size is very hard to obtain under 
500nm
23
. Furthermore, user friendly CLEA synthesis process results in the micron scale 
end product. 
One approach to mitigate these issues has rested on limiting the particle size to the 
nanoscale so as to optimize substrate turnover, while retaining all the stability advantages 
associated with crosslinking
24
. Accordingly, individual protein units have been brought 
together by way of various bottom-up approaches, yielding nanoscale enzyme particles. 
While effective, such attempts have generally proven very laborious, expensive, protein-
specific, lossy, and impractical towards various target proteins
25,26
. In contrast, herein this 
issue is addressed with a generalized procedure suitable for wide range of proteins and 
applications – Namely, physical nanonization of crosslinked protein aggregate particles. 
The principle lies within limiting the particle size to the nanoscale so as to optimize 
substrate turnover, while retaining all the stability advantages associated with crosslinking. 
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This method should also be nicely applicable to CLEC formulations, but has not been yet 
attempted. Up till now protein nano-particle formulations have only been attempted by 
bottom-up approach, technique presented herein is unique in sense that it is based on very 
general and practical size reduction method. 
Depicting the first top-down approach in this area, the success of this strategy rests on 
nanonizing macroscopic precursors via several means, namely application mechanical and 
hydrodynamic shear, under optimized media conditions.  
In the course of this study conventional CLEA approach was pursued in synthesis of 
precursor materials. Optimization of these processes has been performed aiming to better 
accommodate following downsizing procedure. Furthermore, alternative formulations have 
been developed.  
Dehydrothermal crosslinking of lyophilizates strategy, developed in house, is demonstrated 
on Figure 1.4.  Dehydrothermal crosslinking yields zero-length inter-protein amide bonds 
by thermally dehydrating inter-protein ammonium carboxylate salt bridges under vacuum-
assisted conditions. The salt bridges undergoing transformation are made to juxtapose 
beforehand during the lyophilization step. The thermal stability imparted to proteins in the 
dry state and the anoxic processing conditions ensure good retention of bioactivity
27,28
.  
Dehydrothermal crosslinking is particularly attractive in preparing biomaterials, since the 
reagent-free approach eliminates toxicity concerns relating to the use of exogenous 
chemicals.  
 
 
Figure 1.4: Dehydrothemal crosslinking mode of juxtaposed protein functional groups 
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The “pH memory”, a term coined to signify the retention of functional group ionization 
states over the course of lyophilization, has allowed one to optimize many water-free, “pH-
dependent” chemical transformations of a lyophilized material by appropriately adjusting 
the pH of the protein solution prior to lyophilization
29,30
. 
Furthermore, inspired by the efficiency of the lyophilizate approach above, chemical 
crosslinking of lyophilizates in organic media was attempted on challenging protein 
formulations where dehydrothermal method efficiency failed to yield plausibly, giving rise 
to yet another convenient alternative: crosslinked protein lyophilizate (CLPL) formulations. 
Nano-CLEA formulations are aimed to provide a beneficial alternative to conventional 
protein formulation as well establish new potential products.  
Industrial nanoCLEA could address already widely explored fields such as detergent, 
textile, leather industry, food, animal feed industry and biodiesel production and waste 
treatment. Those of course are mainly hydrolytic enzymes and the starting material for 
some of the applications can be very crude. In terms of organic synthesis, novel greener 
catalysis, involving much milder conditions are being attempted, with less hazardous 
reagent, to achieve industrially important small organics synthesis. Stability of the 
nanoCLEA under extreme temperature, pH, and organic solvents conditions makes it a very 
plausible potential catalyst.   In analytical field products such as, sensory and diagnostic test 
enzymes, chromatography media, artificial antibodies are targeted. 
Potential biomedical applications along with biosensors
31
 also include both systemic and 
local therapeutics, aiming topical and internal delivery systems
32,33
. 
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2. Crosslinked Protein Aggregates (CLPA) Optimization Using Conventional 
Techniqes and Introduction of Crosslinked Protein Lyophilizates (CLPL) 
Synthesis 
 
 
 
 
2.1. Introduction and Rationale  
 
 
 
This chapter aims to describe a general methodology leading to crosslinked protein 
aggregates (CLPA) as well as techniques to optimize specific products on the basis of 
protein type. It further introduces the concept of crosslinked protein lyophilizates (CLPL), 
which have been developed over the course of this study.  
Initial studies performed on a number of proteins are briefly described in this chapter to 
exemplify each step of the overall work. Optimization of the method has been described in 
detail on protein models including albumin, trypsin and chymotrypsin. Albumin was 
chosen as an initial model due to its stability and ease of manipulation. Trypsin and 
chymotrypsin were chosen to model the catalysis of proteins transformed into their 
respective CLPAs. Their successful preparation as CLPAs also served to highlight the 
facility of this method in handling autolytic proteins in particular, and forecast similar 
benefits in handling all proteins with limited solution-state stability. The CLPA method was 
also modified to successfully process exceptionally user-unfriendly models such as urease, 
which afforded poor aggregation recoveries, low crosslinking yields and near-zero retention 
of bioactivity when processed using established CLPA fabrication methods. In addressing 
the technical challenges posed by urease, an alternative general aggregation-crosslinking 
method was envisaged to bypass similar intrinsic challenges posed by other user-unfriendly 
proteins. The outcome of that research yielded crosslinked protein lyophilizates, i.e., CLPL, 
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whose success primarily rested on an alternative route to enforce protein aggregation. The 
promise of the CLPL method has since been demonstrated on several protein systems.  
The preparation and optimization of CLPAs in this thesis are based on revisions and 
additions to original work as described by Sheldon et al. Some aspects include: 
Aggregation via salting-out or use of anti-solvent 
Aggregation is normally achieved through crash precipitation of an aqueous protein 
solution. To achieve this end, the protein solution is delivered to a stirred vessel containing 
a suitable high salt aqueous medium or miscible organic antisolvent. Typical media used to 
crash-precipitate have included concentrated aqueous ammonium sulfate, polymers and 
acetone. Long-established alternatives to precipitate protein, such as isoelectric point 
precipitations, have proved lower yielding when used alone. Where appropriate, these 
techniques can be integrated into the crash precipitation step in order to optimize 
aggregation. For instance, for optimal results, the solution pH value can be matched to the 
protein pI immediately before salting-out is conducted. 
Aggregation enforced by lyophilization 
Later described in this work, the use of lyophilization instead of crash precipitation has 
been established as the method of choice to handle proteins, which showed poor 
aggregation out of solution or intolerance to normal aggregation conditions as marked by a 
dramatic loss of activity. Since material loss cannot occur during freezing and drying, it 
was rationalized that the protein aggregate could be successfully and quantitatively 
obtained out of solution through lyophilization in cases where crash precipitation did not 
give the desired result. The one downside of lyophilization over conventional crash-
precipitation is the extra time and equipment needed to dry the material. As part of the 
lyophilization procedure, optimally formulated protein solutions were lyophilized and later 
immersed in a medium – generally and organic solvent - to facilitate the subsequent 
crosslinking step (vide infra). The benefits of aggregation via lyophilization were readily 
apparent in terms of the ease of aggregate recovery and process optimization, high overall 
yields, predictable bioactivity, and easy handling of the dried products for further 
manipulation.  
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Crosslinking  
Covalent crosslinking was achieved via conventional techniques, which utilized reaction of 
protein side chain or terminal functional groups as a means to afford the insoluble 
crosslinked aggregate. These non-specific techniques primarily target the surface-exposed 
and thus chemically reactive amino- and carboxyl- residues. Some reagents and factors 
have been listed below, which prompt covalent crosslinking. 
Aldehydes  
Glutaraldehyde is the most commonly used crosslinking reagent in general as well as 
aldehyde. Its crosslinking efficiency is generally high for proteins undergoing reaction 
under homogeneous phase conditions as well as for aggregated protein powders dispersed 
in solvent. In proteins with low surface lysyl group content, dextran polyaldehyde has 
shown higher yields. Dextran polyaldehyde also provides for milder reaction conditions and 
reduced toxicity risks, thus explaining its preferred use in many biomedical applications. 
Yet another important rationale supporting its use over glutaraldehyde is its greater steric 
bulk. This trait could presumably limit its approach to the active center of enzymes, thus 
reducing the likelihood of deactivation via inadvertent reaction with a lysyl residue 
involved in binding or catalysis. Aldehyde crosslinked protein-protein aggregates are joined 
through bridging reagent moieties.  
Carbodiimides  
Carbodiimides are condensation agents, which act through initial carboxyl group activation, 
leading to zero-length inter-protein amide bonds. Since the o-acylisourea intermediate is 
hydrolytically unstable, crosslinking is often aided by adding auxillary agents such as 
hydroxysuccinimide. Once the o-acylisourea is attacked, hydroxysuccinimide forms a 
hydrolytically stable active ester with the carboxyl residue, thereby prolonging the time 
available for conjugation with amino groups. In our experience, the crosslinking of protein 
powders dispersed in solvent proved less efficient than classical homogeneous phase 
reactions. Adding hydroxysuccinimide to the dispersion proved very useful to ameliorate 
the low crosslinking yields. 
Dehydrothermal crosslinking  
The dehydrothermal crosslinking method was developed in-house. Dehydrothermal 
crosslinking yields zero-length inter-protein amide bonds by thermally dehydrating inter-
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protein ammonium carboxylate salt bridges under vacuum-assisted conditions. The salt 
bridges undergoing transformation are made to juxtapose beforehand during the crash-
precipitation/lyophilization step. The thermal stability imparted to proteins in the dry state 
and the anoxic processing conditions ensure good retention of bioactivity. Dehydrothermal 
crosslinking is particularly attractive in preparing biomaterials, since the reagent-free 
approach eliminates toxicity concerns relating to the use of exogenous chemicals. 
Dehydrothermal crosslinking should not be confused with “dehydrothermal processing”, 
which is a common method practiced on ceramic materials. 
The study described in this chapter highlights new optimization techniques and alternative 
routes to conventional CLPA material synthesis. Furthermore, the principles and methods 
expressed herein will form the groundwork leading to the development of nano-CLPAs and 
nano-CLPLs, which are described in the following chapter. In particular, the material 
synthesized in this chapter will serve as the product precursor of the following chapter, 
yielding nano-sized particles over the course of nanonization. The specific physico-
chemical traits of the precursor material will also reflect the choice of method and 
optimization strategy used in the downsizing process. 
 
 
 
2.2. Materials 
 
 
 
Bovine Serum Albumin was obtained from Sigma-Aldrich. Bovine Serum Albumin, heat 
shock fraction, pH 7, ≥98%  
Trypsin was obtained from PAN Biotech Gmbh. Trypsin powder (1 : 250) porcine origin 
Chymotrypsin was obtained from Sigma-Aldrich. α-Chymotrypsin from bovine pancreas, 
Type II, lyophilized powder, ≥40 units/mg protein 
Jack Bean Urease was obtained from Sigma-Aldrich. Urease from Canavalia ensiformis 
(Jack bean), Type IX, powder, 50,000-100,000 units/g solid  
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Henn Egg Lysozyme was obtained from Sigma-Aldrich. Lysozyme from chicken egg white 
lyophilized powder, protein ≥90 %, ≥40,000 units/mg protein 
Bovine Hemoglobin was obtained from Sigma-Aldrich. Hemoglobin from bovine blood, 
suitable for protease substrate, substrate powder  
All other reagents were obtained from commercial suppliers as analytical grade and were 
used without further purification.  
 
 
 
2.3. General Methods  
 
 
 
In a typical preparation, soluble monomeric protein starting materials were crash 
precipitated or lyophilized, forming macroscopic aggregates. These soft solids were 
chemically directly in aggregation medium or dehydrothermally crosslinked. Choice of 
initial solution composition, aggregation and crosslinking steps were conducted in a manner 
permitting retention, and in many cases, improvement of biological activity.  
Material was further characterized to establish the optimal synthesis conditions in terms of 
overall synthesis yield efficiency and biological activity. 
 
 
 
2.3.1. CLPA and CLPL synthesis 
 
 
2.3.1.1. Precursor protein solutions 
 
All protein solutions were prepared by mild agitation at 4 ºC. Final protein concentrations 
in solution were verified either spectrophotometrically (using molar extinction coefficient, 
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280nm) or by recording the weight of the lyophilized protein of known initial volume 
depending on the further procedure.  
Protein solutions described in this chapter were generally of the following composition: 
 
 
Protein(s) 
Concentration 
(mg/ml) 
Solution composition pH 
Albumin 100-200 
100mM sodium acetate buffer 5,6 
100mM sodium phosphate buffer 7,4 
Trypsin 50-100 
10mM CaCl2 in hydrochloric acid solution 3 
10mM CaCl2 in hydrochloric acid solution 4,5 
10mM CaCl2 in 10mM sodium acetate buffer 5,6 
10mM CaCl2 in 10mM Tris buffer 7,4 
10mM CaCl2 in 10mM Tris buffer 9,2 
Trypsin/ 
Albumin 
50/50 
10mM CaCl2 in hydrochloric acid solution 3 
10mM CaCl2 in hydrochloric acid solution 4,5 
10mM CaCl2 in 10mM sodium acetate buffer 5,6 
10mM CaCl2 in 10mM Tris buffer 7,4 
10mM CaCl2 in 10mM Tris buffer 9,2 
Chymotrypsin 50 
10mM CaCl2 in hydrochloric acid solution 3 
10mM CaCl2 in hydrochloric acid solution 4,5 
10mM CaCl2 in 10mM sodium acetate buffer 5,6 
10mM CaCl2 in 10mM Tris buffer 7,4 
10mM CaCl2 in 10mM Tris buffer 9,2 
Urease 25-100 100mM sodium phosphate buffer 7,4 
Urease/Albumin 10-50/50-100 100mM sodium phosphate buffer 7.4 
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2.3.1.2.  Precipitation 
 
Precipitation procedures were performed with freshly prepared protein solution at 4 ºC, 
through lyophilization or crash precipitation.   
Lyophilization: Protein solutions were submerged into liquid nitrogen, and freshly frozen 
material was lyophilized using Christ brand ALPHA 1-2 LDplus laboratory scale freeze-
dryer (Martin Christ Gefriertrocknungsanlagen GmbH, Germany) (0.02-0.04mbar, 12h). 
Crash Precipitation: Protein solutions were dropwise added into a saturated ammonium 
sulfate solution (salting out) or an anti-solvent under constant stirring conditions at v:v ratio 
of 1:9 and left to stir for 20-30 min at 400-550 rpm, at 4 ºC. Anti-solvents described here 
were methanol, ethanol, acetone, 1-propanol, 2-propanol, 2-butanol, dimethylformamide 
and dioxane. 
*All preparations involving dioxane were performed at room temperature. 
 
 
2.3.1.3.  Crosslinking 
 
Chemical crosslinking: 
Chemical crosslinking of crash-precipitated aggregates was conducted directly in the stirred 
aggregation medium by adding a chemical crosslinking reagent to suspensions of protein 
solution previously incubated with salting-out agent or anti-solvent. To covalently crosslink 
protein lyophilizates, in case of CLPL synthesis, lyophilized powders were immersed in an 
anti-solvent containing crosslinker. 
Glutaraldehyde 
Glutaraldehyde was applied at concentrations of 0.106 x 10
-6
 – 6.36 x 10-5 mol per mg 
protein (dry weight equivalent). Listed below are the amounts of glutaraldehyde used in 
each trial: 
1. 1.064 x 10-6 mol per mg protein 
2. 2.12 x 10-6 mol per mg protein 
3. 0.53 x 10-5 mol per mg protein 
4. 1.06 x 10-5 mol per mg protein 
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5. 2.12 x 10-5 mol per mg protein 
6. 3.18 x 10-5 mol per mg protein 
7. 4.24 x 10-5 mol per mg protein 
8. 6.36 x 10-5 mol per mg protein 
Glutaraldehyde is typically stored and sold at slightly acidic pH values, which serves to 
reduce its optimal reactivity. In this work, commercial glutaraldehyde stocks (25wt%, pH 
5) were directly used without pH adjustment. Alternatively, water-diluted stocks (12.5wt%, 
adjusted to pH 9.2 using 0.1M sodium carbonate buffer and pH 7.4 using 0.1M sodium 
phosphate buffer) were used. Suspension was incubated for 20h while stirring (400 rpm) at 
4°C, if not stated otherwise in the text. Crosslinked material was isolated from reaction 
medium by centrifugation (4krpm) and incubated in 0.1 % sodium borohydryde solution (at 
volume equivalent to the aggregation medium used) at mild agitation (200 rpm). Once all 
imines were presumably reduced (30 min), the crosslinked material was washed thrice with 
double distilled water and dried under vacuum prior to storage (RT). 
Dextran Polyaldehyde 
Dextran polyaldehyde was synthesized in house according to the following procedure
10
: 
Dextran 1.65 g was dissolved in 80 mL of water, and 3.85 g sodium metaperiodate were 
added. The resulting solution was stirred at room temperature during 90 min. Subsequently, 
the solution was dialyzed five times, using a MW cutoff of 10 KDa against 5 L of water 
each time at room temperature during 2 hrs and under stirring. The final volume of the 
dextran polyaldehyde was 87 mL. 
Dextran polyaldehyde was applied at concentration of 0.38 mg or 0.76 mg per mg protein 
(dry weight equivalent) for all samples, if not stated otherwise in the text. Suspension was 
incubated for 20h while stirring (400 rpm) at 4°C, if not stated otherwise in the text. 
Crosslinked material was isolated from reaction medium by centrifugation (4 krpm) and 
incubated in 0.1 % sodium borohydride solution (at volume equivalent to the aggregation 
medium used) at mild agitation (200 rpm). Once all imines were presumably reduced (30 
min), the crosslinked material was washed thrice with double distilled water and dried 
under vacuum prior to storage (RT). 
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Carbondiimides 
1-ethyl-3(3-dimethylaminopropyl)carbodiimide (EDC) and N,N'-dicyclohexylcarbodiimide 
(DCC) crosslinking was attempted. EDC was applied at 5.2x10
-6 – 3.1x10-5 mol and DCC 
at 3.8x10
-6 – 1.9x10-5 mol concentrations per mg protein (dry weight equivalent), with/out 
prior addition of N-hydroxysuccinimide (1.4x10
-5 – 2.8x10-5 mol). EDC was applied to 
ammonium sulfate aggregated suspensions, while CDC was applied to dimethyl formamide 
and 2-propanol aggregated suspensions. Suspension was incubated for 20h while stirring 
(400 rpm) at 4°C, if not stated otherwise in the text. Crosslinked material was isolated from 
reaction medium by centrifugation (4 krpm) and incubated in 0.1 wt% sodium borohydride 
solution (at volume equivalent to the aggregation medium used) for 30 min at mild 
agitation (200 rpm). Reduced material was washed thrice with double distilled water. 
 
In vacuo Dehydrothermal Crosslinking: 
Precursor solutions were flash frozen in liquid nitrogen and lyophilized (0.02-0.04mbar, 12-
48h) without applying external cooling. Prior to in vacuo heating, lyophilizates were 
incubated (RT, 8-12h) in a partially-evacuated desiccator containing solid ammonium 
carbonate (5g), in order to adjust the ionization states to promote efficient crosslinking. 
A make-shift apparatus consisting of a lyophilizer vessel, and a heat-variable oil-bath, was 
employed to drive the in vacuo crosslinking. Pretreated as described, the protein 
lyophilizates were transferred into the glass vessel and incubated under constant evacuation 
(100ºC, 0.2-0.6mbar, 14-20h) with the vessel partially submerged in the oil-bath. The act of 
continuously evacuating the vessel combined with heating hastened the loss of previously 
non-desorbed water as well as water arising from the crosslinking reactions. 
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2.3.2. Characterization 
 
 
 
2.3.2.1.  Determination of aggregation and crosslinking yields  
 
Aggregation yield 
Protein solutions were dropwise added into a saturated ammonium sulfate solution (salting 
out) or an anti-solvent under constant stirring conditions at v:v ratio of 1:9 and left to stir 
for 20-30 min at 400-550 rpm, at 4 ºC, in pre-weighted 50 ml falcon tubes. The formed 
suspensions were centrifuged (4 krpm) and supernatants were removed. The remaining 
precipitate was dried and weighted.  
Corresponding precursor protein solution was lyophilized in the pre-weighted eppendorf 
tube and weighted. The weight of lyophilizate was used as reference in place of protein 
concentration. The aggregation yield was calculated according to the following equation 
(2.1): 
                       
  
  
      (2.1) 
Where Wa and Wl are dry weights of aggregate and lyophilizate respectively. 
All presented data was the mean value of experimental results performed in triplicates. 
 
Crosslinking yield 
Crosslinking was conducted as described above in the pre-weighted 50 ml falcon tubes and 
subsequently reduced with sodium borohydride, where applicable. Formed CLPA was 
washed thrice with distilled water, centrifuged (4 krpm) and resultant precipitate was dried. 
The crosslinking yield was calculated according to the following equation (2.2): 
                        
         
  
      (2.2) 
Where Wclpa and Wa are dry weights of CLPA and precursor aggregate respectively. Wxl 
is the calculated dry weight of crosslinking reagent applied. 
All presented data was the mean value of experimental results performed in triplicates. 
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2.3.2.2. ATR-FTIR molecular structure analysis (*amide area 
flactuations) 
 
Attenuated total reflectance Fourier Transform Infrared Spectroscopy (ATR-FTIR) was 
used to directly monitor changes of dipole moment in amide and other regions as a function 
of protocol (crosslinker type, amount, crosslinking time and temperature) in case of 
chemical reagent crosslinking and as a function of crosslinking time in case of 
dehydothermal crosslinking. The data was then related to changes in material hydratability 
and protein-protein interactions within the material. Prior to analysis, the crosslinked and 
control material were simultaneously pre-incubated (overnight, RT) in a partially-evacuated 
desiccator containing distilled water in order to normalize the hydration level of each 
sample. The vacuum was broken, and ATR-FTIR spectra were acquired. 34 consecutive 
scans were acquired per sample, and the averaged result was baseline-corrected. 
Lyophlizates were clamped along the observation window of an ATR accessory, and 
spectra were obtained from 550 to 4000 cm-1 at a resolution of 0.5 cm−1. 
 
 
2.3.2.3.  Relative bioactivity assays 
 
Proteases 
Relative catalytic activity of proteases was detected by digestion of gelatin incubated for 
two hours at 37ºC, agitated at 450 rpm.  Ninhydrin analysis was performed using spent 
buffer/ninhydrin/isopropanol comprising 100:1:99 [v/w/v] (70˚C, 30min). Color yields 
were analyzed spectrophotometrically (570nm). Native protease solution measurements 
were assigned a value of 100% and CLPA measurements were calculated relative to this 
value.  
 
Urease 
Urease relative catalytic activity was detected by urea degradation upon 30 min incubation 
at 37ºC, agitated at 450 rpm. Ninhydrin analysis was performed using spent 
buffer/ninhydrin/isopropanol comprising 100:1:99 [v/w/v] (70˚C, 30min). Color yields 
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were analyzed spectrophotometrically (570nm). Native urease solution measurements were 
assigned a value of 100% and CLPA measurements were calculated relative to this value. 
 
Lysozyme  
Preliminary studies were performed using the assay based on the disruption of cell wall 
peptidoglycans, resulting in lysis of the bacteria and loss of optical density. 
Micrococcus luteus (ATCC 4698) cells were grown in tripticase soy agar (ATCC medium 
18) medium. In a typical assay, control native lysozyme solution and CLPA suspensions, 
were diluted to a concentration of 0.4 mg/mL. For each sample, an aliquot (100 µl) was 
transferred to 900 µl of cell suspension with an optical density of 0.6A (450 nm). Changes 
of optical density were recorded at each 15-s time interval. The average activity of each 
sample was calculated by averaging every 15-s measurement acquired over the first 3 min. 
Native protein solution measurements were assigned a value of 100% and CLPA 
measurements were calculated relative to this value. 
 
Hemoglobin 
The assay used was a variant of a published procedure
34
. In particular, this method was 
based on the ability of hemoglobin to catalyze the reaction between o-phenylenediamine 
and hydrogen peroxide to form 2,3-diaminophenazine. 
The reaction was initiated by addition of hydrogen peroxide (2x10-3 mM) to a stirred 
native hemoglobin solution or suspension containing hemoglobin CLPA and o-
phenylenediamine (4x10-3 mM). Product formation was spectrophotometrically detected at 
425 nm after one hour of incubation at room temperature, agitated at 450 rpm. All dilutions 
were performed in 100mM phosphate buffer, pH 7,4. Native protein solution measurements 
were assigned a value of 100% and CLPA measurements were calculated relative to this 
value. 
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2.4. Results and Discussion 
 
 
 
The results herein are presented in the chronologic manner. The preliminary results are 
briefly presented first, in order to demonstrate the general behavior of CLPA material on a 
wider range of proteins. It also serves to highlight the challenges and goals of the study and 
rationalize the following optimization approach. Further description of process optimization 
is presented on the model of albumin, trypsin and chymotrypsin.   Optimization of CLPA 
product comes down to synchronization of optimum conditions for three main factors: 
precursor solution formulation, precipitation method and crosslinking method. 
 
 
 
2.4.1. Preliminary methodology studies 
 
 
Preliminary methodology screening was performed on albumin, pepsin, trypsin, 
chymotrypsin, lysosyme, hemoglobin, pancreatic lipase, urease and industrial grade mixed 
enzymes (Maps Enzymes) using Sheldon et al work as the directive. The conventional 
approach has proved satisfactory to some extent in all cases, with an exception of urease, 
which has therefore required thorough optimization discussed in later on, as the most 
challenging case. 
It has become evident from the initial screening, just as described in the corresponding 
literature
35
, that the choice of the technique and solvent is target protein dependent, 
affecting both aggregation yield and catalytic activity of the end product. 
For most of the trial proteins aggregation yield efficiency has not posed an issue (Figure 
2.1.), while crosslinking in the given medium often was found to be a target for further 
optimization, in terms of synthesis efficiency yield.     
 
 
22 
 
 
Figure 0.1: General review of crash precipitation step efficiency. 
 
That being said, not surprisingly aggregation method had a dramatic effect on catalytic 
activity of the final product, in a protein type specific manner (Figure 2.2).  
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Figure 0.2: General review of aggregation method effect on relative catalytic activity of 
CLPA  
 
Subsequent crosslinking is strongly dependent on the previous steps in terms of efficiency. 
The obtained CLPA activity varied strongly both with the method of choice and 
crosslinking degree and as all other is protein type specific (Figure 2.3).  
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Figure 0.3: General review of crosslinking method effect on relative catalytic activity of 
CLPA 
 
 
 
2.4.2. Optimization of precursor protein solutions in terms of CLPA synthesis 
yield and catalytic activity  
 
 
2.4.2.1.  Stability of the protein in solution state 
 
Trypsin model formed a very good model for CLPA optimizations, due to its vulnerability 
in solution state. Particularly, because solution formulations used were of high 
concentration (50-100 mg/mL), the somewhat prolonged process of obtaining a stable 
solution was intercepted by the rapid autolysis. The preliminary studies conducted on 
trypsin CLPA were performed in 10-100mM buffer solutions at various pH values. The 
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catalytic activity of the final product in these formulations gave very poor results in terms 
of result reproducibility, all being under 100% with respect to the native enzyme (results 
not shown). Neutral to high pH formulations in particular, resulted in dramatically 
diminished activity, while acidic formulation resulted in final product activity approaching 
100%. The conventional stabilization approach of co-precipitation with albumin has been 
attempted and resulted in further diminished catalytic activity yields, which was 
rationalized by the decrease in accessible catalytically operational surface area. Addition of 
10-100mM calcium chloride to the precursor solution formulations has evidently aided in 
stabilizing the protein, leading to increased consistency of the results and increased activity 
(Figure 2.4).    
 
Figure 0.4: Precursor solution effect on CLPA catalytic activity. Trypsin CLPA (aggregated 
in acetone, glutaraldehyde crosslinked)  
 
26 
 
The precursor solution related catalytic activity results appear counterintuitive, in terms of 
initial rationalization that aggregates, as lyophilizates
29
 would preserve the ionization states 
dictated by the precursor solution and therefore would perform optimally when aggregated 
under conditions corresponding to the enzyme’s optimum pH and ionic strength. As can be 
observed from Figure 2.4 highest catalytic activity yield for trypsin CLPA was obtained at 
pH 4.5. It may be presumed that this point is optimal in terms of stabilization of the enzyme 
prior to aggregation, while still preserving the operational catalytic site state. Relatively 
lower activity yield at higher pH points appears to be the result of elevated autolysis in the 
solution state. In these improved formulation trypsin/albumin co-aggregated CLPA yields 
have increased insignificantly, further leading to the conclusion that while addition of 
albumin indeed increased the stability of trypsin in the solution state, significant decrease in 
the catalytic surface area accessible to the substrate is the predominant factor. It must be 
emphasized here, that the substrate in question, gelatin, due to its large molecular size 
posses a dramatic diffusion and catalytic site accessibility limitations, as compared to 
trypsin specific amino acid/peptide substrates such as N-benzoyl-L-arginine and N-
glutaryl-L-phenylaline derivatives etc., which have not been used in this study. These 
limitations must be taken into account in over viewing the catalytic activity yields obtained.   
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Figure 0.5: Precursor solution effect on CLPA catalytic activity. Chymotrypsin CLPA 
(aggregated 2-propanol, glutaraldehyde crosslinked) 
 
Predictably, in case of chymotrypsin CLPA, the catalytic activity yield to precursor solution 
relationship was found similar but less pronounced, since this protease is relatively more 
stable in the solution state than trypsin (Figure 2.5).  
 
 
2.4.2.2. Facilitation of further synthesis steps 
 
No statistically significant relationship was found between aggregation yields and precursor 
protein solution formulations. The precursor solution pH, on the other hand, was found to 
greatly affect the chemical crosslinking yields for all attempted protein types, where lysine 
oriented modification methods were applied (Figure 2.6). The result was not surprising 
given reversibility of glutaraldehyde reactions bellow pH 7, which would decrease the 
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number of effective crosslinks formed even with incorporation of borohydride reduction
11
. 
This has posed a challenge considering higher activity yields of trypsin CLPA at lower pH 
conditions; this problem was addressed later on and is discussed in Section 2.4.5.   
Solution conditions have not posed an issue in case of dehydrothermal crosslinking, owed 
to the ionization state equilibration procedure applied to lyophilizates prior to crosslinking 
procedure.  
 
Figure 0.6: Precursor solution effect on crosslinking yield. Trypsin CLPA (aggregated in 
acetone, glutaraldehyde crosslinked) 
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2.4.3. Optimization of aggregation method and protocol in terms of CLPA 
synthesis and catalytic activity 
 
 
As was demonstrated on the preliminary results, optimization of aggregation yield is 
protein specific, but generally is easily achieved. Since the synthesis process dictates 
crosslinking process performed upon aggregation without replacing the medium, choice of 
aggregation medium significantly influences the crosslinking yield. It can be generalized 
that, medium containing functional groups competing (ammonium sulfate solution, 
acetone) for crosslinker reagent somewhat reduces the crosslinking yield, which is partially 
compensated by coincidental effectiveness of aggregation in these media. Albumin 
primarily due to abundant surface lysine content is very readily crosslinked, compared to all 
other attempted protein types; hence the described relationship is minor in case of albumin 
CLPA (Figure 2.7).    
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Figure 0.7: Aggregation medium effect on aggregation (up) and crosslinking yield 
(down).Albumin CLPA (pH 7.4 precursor solution, glutaraldehyde crosslinked) 
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Figure 0.8: Aggregation medium effect on aggregation (up) and crosslinking yield (down). 
Trypsin CLPA (glutaraldehyde crosslinked) 
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As can be observed from Figure 2.8, the relationship between aggregation medium and 
crosslinking yield is much more pronounced in case of trypsin CLPA, a closely similar 
pattern is applied to chymotrypsin CLPA (results not shown). Due to plausible catalytic 
activity output combined with the high crosslinking yield, 2-propanol was generally the 
aggregation medium of choice for further trypsin and chymotrypsin CLPA formulations.  
Effect of aggregation medium on the catalytic activity of CLPA is demonstrated herein on 
trypsin (Figure 2.9), with once again a very close pattern applied to chymotrypsin (results 
not shown). It is generally observed from the literature
36
 and results included in preliminary 
discussion, that the effect of aggregation medium on catalytic activity is strongly protein 
type specific and is difficult to generalize. It can be noted that ammonium sulfate 
precipitation method is relatively mild, and has been widely used for protein purification 
procedures, which is also applicable in case of crash precipitation. In particular cases where 
ammonium sulfate might act as an enzyme inhibitor, it can be readily replaced by an 
alternative inorganic salt with suitable ionic species.  
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Figure 0.9: Aggregation medium effect on CLPA catalytic activity. Trypsin CLPA 
(glutaraldehyde crosslinked) 
 
 
 
2.4.4. Optimization of crosslinking method and protocol in terms of  CLPA 
synthesis yield and catalytic activity 
 
 
The crosslinking method choice dominantly dictates the catalytic activity of CLPA and is, 
as other synthesis steps, protein type specific. 
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Figure 2.10 presents crosslinking method comparison on the example of trypsin. It is 
common to expect higher catalytic yields from milder dextran polyaldehyde crosslinking as 
compared to glutaraldehyde, as is widely mentioned in literature
10
. Nevertheless, the 
activity yield in this case was observed to be statistically insignificant. It can be assumed 
that steric effect plays a significant role here: as was earlier observed in case of co-
precipitation with albumin, the change in accessible catalytic area greatly influences the 
resultant activity. Much bulkier dextran polyaldehyde, while presumably preserving the 
catalytic site altering, is increasing the density of the aggregate network, therefore limiting 
accessibility.  
All protocol variants of carbodiimide crosslinking in all attempted protein types resulted in 
the most poor activity yields relative to other crosslinking techniques employed. The 
method was optimized to satisfy the average crosslinking yield expectation, by adjusting 
carbodiimide to hydroxysuccinimide ratio in the reaction, but since the resultant CLPA 
catalytic activity appeared bellow average the method was not further investigated and still 
remains subject to optimization. One of potential reasons for unsatisfactory activity yields, 
given that the amount the carbodiimide necessary to provide the structural integrity also led 
to excessive intra-molecular modification. This scenario is also probable because of the 
relatively small size of carbodiimide reagent, which could access and modify the catalytic 
site residue of a certain protein fraction. Furthermore additional zero-length bonding, 
combined with the tightened network of the aggregate could lead to restriction of substrate 
accessibility. Further optimization of this method could potentially be particularly 
advantageous in protein types with low available surface lysine content, alone or in 
combination with primary amine oriented crosslinking reagents.  
Dehydrothermal crosslinking, coinciding with preliminary results, yielded highest catalytic 
activity. The results are not surprising, given the lyophilizate dictated high porosity of the 
crosslinked product, facilitating substrate accessibility. Furthermore as it has been shown 
before, this technique appears relatively mild, due to probably much fewer crosslink 
formations, which are sufficient to obtain high synthesis yield of the insoluble product, as 
compared to chemical crosslinking. Reagent free method furthermore eliminates risk of 
catalytic site modification, as in case of small crosslinking reagents.    
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Figure 0.10: Effect of crosslinking method on CLPA catalytic activity. Trypsin CLPA (pH 
4.5 precursor solution, aggregated in 2-propanol) 
 
The similar effect was observed on the example of chymotrypsin (Figure 2.11) 
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Figure 0.11: Effect of crosslinking method on CLPA catalytic activity. Chymotrypsin 
CLPA (pH 7.4 precursor solution, aggregated in 2-propanol) 
 
Initial pH of the used crosslinking reagent has had a significant effect on catalytic activity, 
while resulting in only minor fluctuations in CLPA synthesis yield. The effect of 
glutaraldehyde and dextran polyaldehyde initial pH on trypsin CLPA activity is 
demonstrated on Figures 2.12 and 2.13 respectively. 
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Figure 0.12: Effect of crosslinking reagent (glutaraldehyde) and pH on CLPA catalytic 
activity. Trypsin CLPA (pH 4.5 precursor solution, aggregated in 2-propanol) 
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Figure 0.13: Effect of crosslinking reagent (dextran polyaldehyde) and pH on CLPA 
catalytic activity. Trypsin CLPA (pH 4.5 precursor solution, aggregated in 2-propanol) 
 
While synthesis yield increases with increasing crosslinking extent, there obviously exists 
an optimum crosslinking degree in terms of catalytic activity. Clearly, optimization should 
be made, utilizing the amount of reagent necessary for structural integrity and recovery of 
insoluble aggregate, while taking the catalytic activity of the resultant product into account. 
Among the proteins attempted for CLPA synthesis albumin has been most readily 
crosslinked example. Figure 2.14 demonstrates glutaraldehyde amount effect on synthesis 
yield and resultant catalytic activity on of trypsin CLPA, which provides an average 
example of globular protein crosslinking.  Methods 4. and 5. (1.06 x 10
-5
 and 2.12 x 10
-5
 
mol of glutaraldehyde per mg protein respectively) were generally employed in all data 
provided in this and next chapter, providing the optimum yield to catalytic activity 
relationship.    
39 
 
 
Figure 0.14: Crosslinking degree effect on CLPA catalytic activity. Trypsin CLPA (pH 4.5 
precursor solution, aggregated in 2-propanol, crosslinker glutaraldehyde)                                                              
* numbers 1-8 represent amount of crosslinker applied: 1. 1,064x10
-6
; 2. 2,12x10
-6
;            
3. 0,53x10
-5
; 4. 1,06x10
-5
; 5. 2,12x10
-5
; 6. 3,18x10
-5
; 7. 4,24x10
-5
; 8. 6,36x10
-5
 mol per mg 
protein 
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Attenuated total reflectance Fourier Transform Infrared Spectroscopy (ATR-FTIR) was 
used to directly monitor changes of dipole moment in amide and other regions as a function 
of crosslinking degree and to compare structural changes implemented by different 
crosslinking methods. The data was then related to changes in protein-protein interactions 
within the aggregate/lyophilizate. 
Since IR spectral intensities are influenced by sample population, peak intensity ratios 
within each sample spectrum were analyzed with respect to the adjacent minima values, 
rendering the analyses independent of the sample amount. IR could be effectively used 
herein to probe the material structure and any relative changes upon crosslinking, 
particularly with regard to the secondary structure. Among the signals acquired, changes of 
amide I/II intensity are compared in detail. 
Herein, amide I (i.e., C=O stretching, 1650 cm
-1
) and II (i.e., N-H bending, 1540 cm
-1
) 
bands appeared to display a minor relative difference of intensity. The structural change in 
protein depending on the crosslinking degree was monitored on the basis of this 
spectroscopic difference, which showed a definite change in the ratio of amide I and II band 
intensities with the increasing amount of crosslinking reagent (Figure 2.15).  
These changes appeared to reflect incremental secondary structural changes as a function of 
crosslinking degree. Presented graphically (Figure 2.16, up), the relative increase of the 
amide I versus amide II band intensity can be observed with increasing crosslinker reagent 
amount. Small but certain relative changes in bond polarization pointed to hydrogen bond 
redistribution. 
Observed were spectral differences most likely related to minor covalent changes, i.e., 
changes which likely influenced structural compliancy, the course of re-hydration, and 
protein-protein hydrogen bonding. A gradual “tightening” of the inter-protein structure was 
envisaged, as such a scenario would reflect not only the incremental formation of crosslinks 
but also the spectroscopic changes. Altered non-covalent inter-protein bonding would also 
almost certainly be expected to contribute to the observed spectral profile of this 
“tightened” protein model37. The increasingly pronounced band corresponding to alkane C-
H bending (1350-1480 cm
-1
) further supports the model
38
. 
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Furthermore, the reversal of C-O stretching (around 1100 cm
-1
) and amide II band has been 
detected after a certain crosslinking degree (Figure 2.16, down), coinciding with the drop of 
catalytic activity discussed earlier on the example of trypsin (Figure 2.14). These changes 
might be pointing out the accumulation of access glutaraldehyde, possible polymerized into 
ether containing species. 
 
 
Figure 0.15: FTIR spectra of glutaraldehyde crosslinked albumin CLPA. *0 represents 
native lyophilized albumin and numbers 2-8 represent amount of crosslinker applied: 2. 
2,12x10
-6
; 4. 1,06x10
-5
; 6. 3,18x10
-5
; 8. 6,36x10
-5
 mol per mg protein 
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Figure 0.16: Ratio of IR band intensities versus crosslinking degree. Glutaraldehyde 
crosslinked albumin CLPA. * 0 represents native lyophilized albumin and numbers 2-8 
represent amount of crosslinker applied: 2. 2,12x10
-6
; 3. 0,53x10
-5
; 4. 1,06x10
-5
; 5. 2,12x10
-
5
; 6. 3,18x10
-5
; 7. 4,24x10
-5
;    8. 6,36x10
-5
 mol per mg protein 
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Figure 2.17 represents qualitative comparison of IR spectra obtained from CLPA 
crosslinked using different methods. Keeping with discussion above it can be observed that 
dehydrothermal crosslinking (Figure 2.17-2) gave rise to much milder structural changes 
compared to chemical crosslinking methods.  
Dextran polyaldehyde crosslinked CLPA (Figure 2.17-4) while resembles glutaraldehyde 
crosslinked (Figure2.17-3) spectrum, clearly reflects polymer incorporation (C-O stretching 
peak) 
 
 
Figure 0.17: FTIR spectra of 1. Native lyophilized albumin and 2. Dehydrothermally 3. 
Glutaraldehyde 4. Dextran polyaldehyde 5. Carbodiimide crosslinked albumin CLPA 
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2.4.5. Special case CLPA optimization and Introduction of CLPL  
 
 
The challenges confronted while attempting urease CLPA synthesis have led to 
development of alternative/supplementary methodology. 
In the case of urease conventional methods for both aggregation and crosslinking have 
failed. The highest precursor solution achieved was 50 mg/mL in 10 mM pH 7.4 phosphate 
buffer. Out of precipitation medium trials, acetone and dioxane provided the highest yield, 
which did not exceed 10%. Any of the above described crosslinked methods further 
decreased the yield, resulting in the trace amount of CLPA formation. Dehydrothermal 
crosslinking method was attempted in order to overstep the aggregation problem, but did 
not result in any significant yield. That could be presumed to occur due to the lack of 
sufficient number of free surface lysine residues in urease structure. 
Co-precipitation with albumin at different urease to albumin weight ratios was attempted 
aiming to both improve aggregation and provide additional lysine residues to aid inter-
protein crosslink formation yield. This has led to slight improvements: It could be safely 
assumed that aggregation and crosslinking of urease fraction was still way below 20%. 
Saturated ammonium sulfate solution, acetone and dioxane precipitations provided highest 
CLPA yield. The catalytic activity measurements on these samples still showed negligible 
results, acetone precipitation leading to complete loss of activity. Crosslinking with pH 9.2 
adjusted glutaraldehyde reagent appeared the most efficient.  
The first breakthrough was achieved by applying “solution pre-crosslinking assisted” 
method, this was performed in order to capture urease out of solution state, making use of 
few inter-protein crosslinks formed. One tenth of the regular crosslinking reagent amount 
was applied to urease/albumin solution 1-5 minutes prior to precipitation. This application 
has finally led to some reproducible results, with while still much below average increased 
catalytic performance (Figure 2.18).  
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Figure 0.18: Catalytic activity of urease CLPA obtained by “precursor solution pre-
crosslink assisted” method  
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While, dehydrothermal crosslinking method did not succeed, it became obvious that 
lyophilization was the only feasible way of efficient capturing with high yield. This 
realization has led to the idea of chemically crosslinked protein lyophilizates (CLPL) 
synthesis, and was carried out as follows: 
Same precursor urease solution formulations were lyophilized and submerged in a 
crosslinking reagent containing anti-solvent. Choice of an anti-solvent was made out of 
those facilitating highest yield in previous aggregation attempts.  
Figure 2.19 demonstrates much improved catalytic activity yields obtained by the described 
method. Crosslinking efficiency, on the other hand, remained the subject to further 
optimization, yielding 10-30 % with the developed technique. All further synthesis 
optimization and utilization of urease CLPL material is within the scope of another ongoing 
Doctorate Thesis.   
 
Figure 0.19: Catalytic activity of urease CLPL  
The technique developed herein, on the most challenging example of urease, has led to 
solutions for issues mentioned earlier in the text, particularly related to all 
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aggregation/crosslinking yields below 100%. Herein it was applied in further optimization 
of less challenging proteins, aiming to address the drawbacks of earlier developed methods. 
The earlier discussed issue of crosslinking yield of trypsin and chymotrypsin CLPA 
formulation, especially in the case of low pH precursor solutions was completely resolved, 
making use of ionization state adjustment applied to lyophilizates prior to crosslinking, 
same way as employed in dehydrothermal crosslinking technique. Protein lyophilizates 
prepared in this manner were immersed in crosslinker reagent containing 2-propanol. This 
technique led to 98-100% synthesis yield with statistically insignificant fluctuation between 
different precursor solutions. 
Significant change in the crosslinker type effect as compared to corresponding CLPA 
formulations was observed in cases of both trypsin (Figure 2.20) and chymotrypsin CLPL. 
Glutaraldehyde crosslinking led to almost complete catalytic deactivation, while much 
improved catalytic yields were detected in dextran polyaldehyde crosslinked CLPL, as 
compared to corresponding CLPA. It is assumed that the dense aggregate network has 
aided in protection of CLPA from excessive intra-protein modification, while much higher 
porosity bearing lyophylizates were intolerably affected. On the other hand, less bulky 
morphology has led to decreased accessibility limitations observed in dextran polyaldehyde 
crosslinked CLPA, resulting in significantly improved catalytic activity, particularly in the 
case of chymotrypsin (Figure 2.21). 
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Figure 0.20: Catalytic activity of trypsin CLPL  
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Figure 0.21: Catalytic activity of chymotrypsin CLPL  
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3. Generation and Characterization of Nano-CLPA and Nano-CLPL Materials  
 
 
 
 
3.1. Introduction and Rationale  
 
 
 
This chapter aims to describe general methodology of nano-CLPA generation technique 
developed herein as a function of nanonization conditions with respect to precursor CLPA 
protein type and synthesis protocol.  
As opposed to the previous chapter methodologies described herein are not based on any 
existing study and form an entirely novel top-down approach to generation of nano-sized 
protein catalysts, namely physical downsizing of macroscopic CLPA/CLPL precursors, as 
opposed to conventional bottom up approach. The macroscopic material is downsized by 
direct application of mechanic or hydrodynamic shear force in an optimized medium. The 
general method developed herein attempts to address concerns familiar to heterogeneous-
phase aqueous, as well as nonaqueous, enzymatic processes such as mass transport and 
diffusion limitations, reduced access to catalytic centers, restricted catalytic turnover arising 
from crosslink-prompted structural rigidity or poor coordination. Under optimized 
conditions, the resultant nano-particle catalyst was consistently more active than its 
crosslinked precursor, showing that in addition to the processing history, the apparent 
activity for a given amount of protein also depended on particle size when transcending 
from the micron to sub-micron scale. 
The scope of this Chapter is focused on the methodology development and optimization, 
rather than fundamental kinetic study of heterogeneous nano-particle catalyst system, 
which would form the main subject of the future work.  
The technique has been applied to all protein CLPA/CLPL described in Chapter 2, 
therefore demonstrating general applicability of the method. Methodology optimization is 
typically described on a model of albumin and trypsin and chymotrypsin. Following the 
51 
 
pattern of Chapter 2, albumin has been chosen as an initial model due to its stability and 
ease of manipulation. The trypsin and chymotripsin models were in order to investigate the 
catalytic activity of CLPA and nano-CLPA formulations, while also serving as an example 
of handling a protein with low solution state stability, in this case due to high autolysis 
activity. Furthermore, commercially obtained Savinase® CLEA (CLEA Technologies) has 
been used in nano-CLPA fabrication in order to compare a conventionally available protein 
formulation with its nano-CLPA alternative developed in house.   
Generation of nano-particles of the defined size in the range of 100-900 nm was 
successfully achieved herein, aiming to be utilized in a wide range of industrial, analytical 
and biomedical applications. The emphasis of the work conducted was to establish the 
general methodology and guidelines to achieve any particle size of the CLPA formulation 
in question in the range of 100-900 nm size with maximum yield and homogeneity, rather 
than discussing specific application requirements.   
 
 
 
3.2.  Materials 
 
 
 
Sample of Savinase® CLEA was provided by CLEA Technologies. 
Other proteins were obtained as described in Chapter 2. 
All other reagents were obtained from commercial suppliers as analytical grade and were 
used without further purification. 
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3.3. General Methods 
 
 
 
CLPA and CLPL formulations were synthesized via techniques optimized/developed in 
Chapter2. The aggregation and crosslinking steps were conducted in a manner that 
facilitated effective nanonization, while permitting retention, and in many cases, 
improvement of biological activity. Subsequent to crosslinking, nanonization was realized 
through hydrodynamic shear or mechanical shear. Grinding aids were typically added to 
facilitate nanonization and retention of the highest possible bioactivity. 
 
 
Figure 3.1: Flow chart summarizing the overall synthesis and optimization process 
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3.3.1. Nano-CLPA generation 
 
 
Precursor CLPA formulations were synthesized as described in Chapter 2. All nanonization 
procedures should be viewed upon as a function of the given precursor formulation, both as 
protein type and CLPA synthesis steps, as signified throughout the discussion.   
 
 
3.3.1.1.  Mechanical shear 
 
Mechanical shear application was performed in an agate mortar with shear force applied by 
hand. Alternatively Gelimat compounder was employed in initial and scale up downsizing 
experiments at a rate of 2-6 krpm for the duration of 5-30 min. Sucrose or potassium 
chloride was used as an additive at 1:1 or 1:2 additive:CLPA weight ratio.  
 
 
3.3.1.2.  Hydrodynamic shear 
 
Preliminary homogenization procedures were performed in standard laboratory scale 
homogenizer at 1-10 mg CLPA per 1 ml medium. Homogenization medium was composed 
of aqueous solutions of sucrose or potassium chloride at concentrations varying at 0-10 
mg/ml. Homogenization was performed at a rate of 2-6 krpm for the duration of 5-30 min.  
Further homogenization procedures were performed in SilentCrusher M homogenizer 
(Heidolph Instruments GmbH & Co.KG) at a 2.5 mg protein per 1 ml medium.  
Homogenization medium was composed of 0-70 wt% aqueous glycerol solution or 70-100 
wt% ethanol. Sucrose or potassium chloride was used as additive at 0-10 mg/ml 
concentrations. Homogenization was performed at a rate of 5-20 krpm for the duration of 5-
30 min. 
CLPA was typically dried and weighted prior to being transferred into homogenization 
medium, where not specified otherwise.  
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3.3.2. Analysis 
 
 
3.3.2.1.  Scanning electron microscopic (SEM) structural analysis 
 
CLPA powder was subjected to treatment in an Emitech brand K950X model carbon 
coater. An approximate coating thickness of 2-3nm was targeted. The processed samples 
were loaded into the vacuum chamber of a ZEISS brand LEO SUPRA 35VP model SEM 
with GEMINI column. An electron gun voltage of 2kV was employed throughout the 
analyses. 
 
 
3.3.2.2.  Dynamic light scattering (DLS) particle size analysis 
 
For initial screening (data presented in section 3.4.1), 1ml homogenized samples were 
centrifuged at 1krpm to separate from residual micron sized particles prior to DLS analysis, 
all further data obtained was collected without centrifugation step. The sample was diluted 
10 fold in medium corresponding to their homogenization conditions. DLS data was 
collected on samples equilibrated at 25 ºC in 2ml disposable cuvettes, as a result of 3 
consecutive scans, Malvern Zetasizer NANO ZS. Absorption of each sample was measured 
at 633 nm and included in DLS measurement protocol. Particle refractive index of 1,5 was 
assumed for all CLPA samples and refractive index of corresponding medium were 
included in the protocol. Data was analyzed using protein analysis model, Malvern 
Zetasizer software. 
 
 
3.3.2.3. Determination of nanonization yield  
 
Nanonization yield was established by centrifugation (0,7-2 krpm, 5-10 min) of the 2ml 
aliquot of homogenized suspension in the pre-weighted eppendorf tube. Formed precipitate 
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was isolated, washed thrice, vacuum dried and weighted. The nanonization yield was 
calculated according to the following equation (3.1): 
                             
  
  
      (3.1) 
Where Wp and Wt are dry weights of precipitate obtained upon centrifugation and total 
weight of CLPA in the 2ml suspension aliquot prior to homogenization (dry weight 
equivalent) respectively. All presented data was the mean value of experimental results 
repeated 6 times. 
Supernatant obtained from centrifugation was used in order to establish centrifugation 
conditions necessary to isolate the submicron fraction of the homogenized suspension. The 
process was conducted interactively with DLS measurements, starting with 5min 0,7 krpm 
centrifugation conditions and increasing the speed and time of centrifugation after each 
measurement until no residual micron sized particles could be detected. This fine tuning 
procedure had to be performed for every sample separately. The centrifugation conditions 
determined in this manner were used in the nanonization yield determination described 
above. 
 
 
3.3.2.4.  Relative bioactivity assays 
 
Relative catalytic activity measurements were performed as described in Chapter 2. 
Methods. Where applicable, nano-CLPA in homogenization medium was dialyzed 4-5 
times (depending on the viscosity of homogenization medium), for at least 4 hours each, 
against buffer solution prescribed for the given analysis, using a MW cutoff of 10 KDa,  
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3.4.  Results and Discussion 
 
 
 
In the similar manner to chapter 2 herein the nano-CLPA generation procedure is described 
in two parts. First, the initial screening is briefly described, therefore providing a short 
history of the methodology development process, followed by detailed description of 
process optimization on the model of albumim, trypsin and chymotrypsin.    
 
 
 
3.4.1. Initial methodology development 
 
 
Feasibility and ease of physical downsizing method has been demonstrated on the first 
attempt. Surprisingly nanoparticle content could even be obtained while using an agate 
mortar with shear pressure applied by hand. The very simple mechanical down-sizing 
method proved convenient in providing rapid proof of down-sized, catalytically competent 
material, and instrumental in revealing the embrittled quality of crosslinked aggregates. 
However, down-sizing proved impossible to reproduce, as shear was being applied 
manually. In contrast, the post-nanonization traits of CLPAs subjected to machine-
calibrated homogenization proved reproducible, providing a convenient basis to 
systematically explore the nanonization phenomena in terms of a range of applied shear, 
amongst other parameters. 
Gelimat compounder was successfully used for mechanical shear application, but due to the 
technical limitations could only be employed in scale up pilot trials, with the minimum 
overall weight of 100g material.  
Alternatively homogenizer was used for application of hydrodynamic shear. Figure 3.2 
presents a DLS measurement of supernatant (1krpm) (a) lysozyme CLPA suspended (b) 
lysozyme CLPA suspended and homogenized in 5mg/ml potassium iodide solution. This 
data provided evidence of nanoparticle content generation upon nanonization procedure, 
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since only residual monomeric lysozyme particles can be observed in the unprocessed 
CLPA sample.  
 
Figure 3.2:  Raw DLS data presentation of crosslinked lysozyme aggregates (a) before and 
(b) after nanonization with 5 mg/ml potassium iodide 
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Figure 3.3: SEM images of lysozyme (a) CLPA, (b) homogenized and (c) grinded nano-
CLPA 
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Figure 3.3 presents the preliminary SEM imagery results illustrating the morphology and 
approximate size order of crosslinked lysozyme precursor material (a), hydrodynamically 
nanonized crosslinked precursor (b), and mechanically nanonized crosslinked precursor (c). 
The precusor lysozyme material appeared micron-sized, while material subjected to shear 
appeared nano-sized and highly polydisperse. In contrast to crosslinked precursor material, 
noncrosslinked lysozyme aggregates readily dissolved under homogenization conditions, 
and yielded unretrackable smears during manual mechanical shearing. Material prepared 
using other proteins types displayed the same trend (SEM results not shown). In targeting 
various particle sizes, the average size and distribution obtained clearly showed protein 
type variability. 
Furthermore, even in the initial trials it could be detected that, irrespective of protein type, 
the CLPA preparation method and subsequent size-reduction conditions influenced 
nanonization.  
Unlike particle size, catalytic activity was less predictable. As plethora of literature implies 
catalytic activity was influenced by the processing history leading to CLPA formation, 
namely, the methods used to aggregate and crosslink protein. The basis of their influence 
on activity rested on providing conditions, which would permit retention of catalytically-
competent structure and sufficient conformational flexibility over the course of the solute-
to-solid phase transition and crosslinking step, which was discussed in length in previous 
Chapter.  
The nano-CLEAs were consistently more active than their crosslinked precursors, showing 
that in addition to the processing history, the apparent activity for a given amount of protein 
also depended on particle size when transcending from the micron to sub-micron scale. 
Since nanonization was not anticipated to invoke static or dynamic alterations to the 
network arrangement, the improved rates also confirmed a gradual transition from 
diffusion-control to reaction-control in proceeding from micron- to submicron-sized 
particles. While the generality of this transition has not been confirmed here directly, the 
predominance of diffusion at the multi-micron scale was clear in any case.  
Still, the predominance of diffusion-control was not overwhelming as could have been 
anticipated particularly for high molecular weight substrates. Previous work on micron-
sized crosslinked enzyme crystals
17
, which showed that substrate diffusion or active-site 
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access were not drastic determinants of overall activity as previously feared, contributing 
only marginally to changes of activity compared to more important factors such as protein 
rigidity.  Enormous substrates notwithstanding, apparent rate differences between native 
state and nano-CLPAs were not likely diffusion-related. Rather, the underlying factors 
would relate to the protein itself. In aqueous media, these would include shifted pH optima 
and other stereoelectronic effects, protein-crosslinker compatibility, and reduced 
conformational freedom. Indeed, protein-protein juxtapositioning has been shown to 
perturb pKa value and nucleophilicity, which could prove advantageous or otherwise
39
. 
Improperly-chosen or sub-optimally utilized crosslinkers could knock-out residues 
important to binding or catalysis without altering the protein global structure, yielding an 
apparent reduction of overall activity. Ironically, neighbor- and crosslinker-induced 
restrictions of conformational freedom will also reduce the protein’s entropy per unit time. 
The end result would be Gibbs ground state elevation of individual proteins in the CLPA, 
yielding more reactive catalysts. While the weight-averaged contributions of these terms 
are subject to variability, it would appear, given the net rise of activity that catalytic losses 
due to crosslinking had not substantially contributed in the case of the optimized nano-
CLPA formulations attempted herein.  
Further supporting this claim, most of the catalytic activity yields described here and 
throughout optimization results, appear very closely related to results obtained for the 
corresponding precursor macroscopic CLPA. The consistent yield increase does not 
conceal the distinct pattern dictated by CLPA formulation, demonstrated in the previous 
Chapter.   
While bond rupture was not confirmed, covalent changes inevitably accompanied the 
nanonization process, given the established chemistry of aldehyde-based reductive 
crosslinking. Barring that fraction of broken bonds, which failed to yield two 
nanoaggregates from one, all proteins directly involved in bond rupture would necessarily 
define the outermost shell of the resultant aggregate. With a shell thickness comparable to 
the typical protein diameter of 3-5nm, a typical nanoaggregate of 500nm diameter would 
contain at least 105 catalytically competent proteins in the underlying layers. Hence, 
activity losses related to bond rupture were presumably insubstantial as opposed to serious. 
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That being said the mechanical behavior implemented by the nature precursor CLPA, 
greatly affected both nanonization efficiency and applicability of nanonization in terms of 
stability under shear applied, some not able to withstand the high shear conditions. Both are 
discussed within the scope of nanonization procedure optimization.   
Initial trials with shear speed approximately equal to that of Gelimat compounder resulted 
in similar output both in terms of particle size and final activity of the resultant nano-CLPA 
(Figure 3.4), showing comparability of the two techniques. All of the trials resulted in nano 
particle content formation and increase in relative catalytic activity compared to the micron 
sized precursors. That being said, size distribution homogeneity and overall nanoparticle 
content efficiency appeared higher with application of mechanical shear (up to 70%). While 
a very low percentage of particles in initial formulations of homogenization medium was 
nanonized (up to 10%). Yet, due to the described material amount limitations, Gelimat 
compounder grinding could not be used for initial screening purposes and was only later on 
applied on industrial grade enzyme mixtures (MAPS enzymes) to prove applicability of a 
scale up process.     
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Figure 3.4: Preliminary review of nanonization method effect relative catalytic activity of 
CLPA 
 
Figure 3.4 expresses the relative activity of native lysozyme, trypsin, and hemoglobin, as 
well as their micron-sized CLPAs and nanonized CLPAs. Bioactivity for the particular 
experimental protocol adopted in these preliminary experiments was least in the micron-
sized CLPAs, intermediate in the native soluble protein, and highest in the nano-CLPAs. 
The most dramatic drop in proceeding from native to micron-sized CPLA was in lysozyme, 
with 60% relative activity being observed. The result is not surprising, given the enormous 
size of the substrate in the assay employed here, based on the digestion bacterial wall. The 
other two protein CLPAs showed approximately higher relative activity. Activity in the 
nano-CPLAs slightly varied amongst the three proteins, reflecting relative activity increases 
ranging from 40-85% compared to native protein. Activity tested comparable amongst the 
two nanonization methods for a given protein. The above trend could not be generalized, as 
other proteins, or sub-optimally prepared nano-CLPA variants of a particular protein, 
yielded higher activity in the native state compared to the corresponding nano-CLPA 
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(discussed later in the chapter). It was true for all proteins tested that nano-CLPAs gave 
higher conversions than the corresponding micron-sized CLPA. The extent of this 
improvement for the particular protein, was very strongly dependent on the size of the 
substrate employed, increasingly pronounced with large substrates. This can be observed 
from the insignificant fluctuation of hemoglobin CLPA upon nanonization.  
The shear speed of Gelimat compounder and homogenizer employed in these initial trials 
could only be controlled approximately, with an error reaching 1krpm.  
For all further optimization purposes homogenization method was employed. These initial 
trials have been conducted on all of the proteins described in Chapter 2. Homogenizer 
employed at this point (SilentCrusher M homogenizer, Heidolph Instruments GmbH & 
Co.KG) has facilitated much higher operational precision and time with applicable shear 
speed up to 25 krpm.  
Parameter that could conclusively be tested at this point was the effect of additives on 
overall nanonization efficiency and size distribution (Figure 3.5). As has been initially 
rationalized, addition of salts and small sugars was found to facilitate the nanonization of 
relatively soft CLPA material, serving as grinding aid. The negligible nanonization yield 
was recorded in additive free medium, for both grinding and homogenization experiments. 
On the other hand, concentration of additives had an effect to a much less significant extent 
than could be expected. Furthermore, amongst the attempted additives, the nature of 
additive had negligible effect on the efficiency of nanonization. Addition of 2,5-5 mg/ml of 
both potassium chloride and sucrose appeared to yield highest nanonization efficiency and 
these concentrations of additives in homogenization medium were used in all further trials, 
unless otherwise specified in the text. 
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Figure 3.5: Effect of additive incorporation in the homogenization medium on nanonization 
yield. (Albumin CLPA was homogenized at 20 krpm, 30 min) 
  
The other major role of additives was in arresting irreversible agglomeration of the particles 
after homogenization, as was shown by the dialysis of particles against double distilled 
water upon homogenization, which resulted in highly unstable suspension as detected by 
DLS analysis (results not shown). The use of relatively high ionic strength buffers (PBS) 
for dialysis has proven sufficient for relative stabilization of the nanoparticle preparations, 
avoiding irreversible agglomeration of the particle resuspendable upon agitation
40
.  
In order to investigate the homogenization speed and time as parameters, experiments were 
conducted in the range of time (5-30 min) and speed (5-20 krpm) in medium consisting of 5 
mg/ml potassium chloride in double distilled water. The general effect of homogenization 
speed and time could be summarized here. As demonstrated on Figure 3.6 nanonization 
could be achieved after periods as short as 5 min, but in order to achieve higher size 
distribution homogeneity longer homogenizations time were required. While some decrease 
in overall particle size was observed with increasing homogenization time, this parameter is 
65 
 
best used to optimize size homogeneity quality, rather than size fine tuning parameter. On 
the contrary homogenization speed formed the main parameter in adjusting the desired 
particle size. With the systematic pattern of higher shear rates generate lower size particles 
(Figure 3.7). 
While somewhat enhanced, the overall nanonization efficiency rarely exceeded 20 % with 
still highly heterogeneous size distribution of the nanonized fraction.  
 
Figure 3.6: Effect of homogenization time on nanonization efficiency. (Albumin CLPA was 
homogenized at 20 krpm) 
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Figure 3.7: Effect of homogenization speed on nanonization efficiency. (Albumin CLPA 
was homogenized for 30 min) 
 
Higher concentrations of protein per medium volume were tested, in attempt to increase the 
yield of homogenization, but did not result in improved efficiency. Furthermore higher 
protein suspension densities often led to decrease in quality of the resultant sample and 
occasional clogging of the homogenizer propeller. 
All attempts to separate particles into size fractions through sieves and membrane filtration 
has failed even with the finer quality samples. It could be derived that clogging occurs not 
only due to highly heterogeneous distribution and presence of residual micron sized 
particles of the lower quality samples, but rather due to intrinsic properties of CLPA 
material. Centrifuge separated nano particle fractions also appeared to clog the sieves. 
Therefore, the only technique employed herein and throughout the further optimization 
experiments was centrifugation ranging from 1 to 4.5 krpm, assuming complete 
precipitation of the particles at higher speeds. All DLS measurements were conducted on 
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the supernatants of homogenized samples centrifuged at 1 krpm in preliminary studies 
described above, in order to eliminate large portion of residual micron sized particles. 
 
 
 
3.4.2. Optimization of nanonization conditions in terms of nanonization yield 
and size reduction efficiency and consequent final product catalytic 
activity 
 
 
 
The initial study has established the general technique, and proved the merit of 
unprecedented top-down approach. Yet, while one of the argued benefits of the developed 
material was the high synthesis yield of the precursor CLPA, dramatically low efficiency of 
nano-particle generation seemed to defeat the purpose. Therefore further research has 
focused on overall yield enhancement, along with narrowing the range of desired particle 
size distribution for any given CLPA formulation.    
 
 
3.4.2.1.  Homogenization medium effect on yield and size reduction 
efficiency 
 
One of the benefits of hydrodynamic shear versus mechanical shear could not be accounted 
for during initial trials: that is the benefit of using homogenization medium composition in 
order to manipulate fine tuning of particle size, and enhance overall nanonization efficiency 
and provide convenient size separation out of nanonized mixture.  
Incorporation of aqueous glycerol solutions into homogenization medium was first 
attempted aiming to provide more efficient size fraction separation through centrifugation 
of generated polydispersed nano-particles
41
. The encountered result has exceeded 
expectations, addressing the problem of low overall sub-micron particle generation yield 
during the homogenization process. 
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Figure 3.8 summarizes the hydrodynamic diameter of nano-CLPAs of albumin as a 
function of the wt% glycerol in water. For a particular CLPA preparation, homogenization 
time, shear speed, salt concentration and %wt range, the mean hydrodynamic diameter 
varied from 600 nm in 0wt% glycerol to 230 nm in 70wt% glycerol. Within these extremes, 
a steady, monotonic decrease of mean diameter was noted as a function of increasing wt% 
glycerol. Glycerol values of 10-50wt% appeared to yield a linear profile, with slight 
concave-up deviations being noted at both wt% extremes. 
In addition to the decrease of particle diameter, the error bars, or absolute size distribution, 
had also narrowed with increasing glycerol concentration. In some cases, optimized 
nanonization media had afforded size variations of less than 100nm (data not shown). 
Viewed in relative terms (i.e., size distribution / mean diameter), the homogenized albumin 
CLPA revealed constant product polydispersity over the full range of glycerol trials. 
Similar downsizing trends were noted for other CLPA preparations, with particle sizes and 
size distributions showing variation according to the different protein types and CLPA 
protocols. Most importantly, increased glycerol content had significantly improved yields 
in the sense that more sub-micron particles could be generated for a given amount of 
CLPA. 
The near-linear trend between mean particle diameter and wt% glycerol indicated near-
ideal weight-averaged contributions of water and glycerol in the homogenization medium. 
The correlation also implied that protein CLEA preparations, properly calibrated at a fixed 
homogenization temperature, rate and time, could be downsized with good predictability 
simply by adjusting the ratio of components of the homogenization medium.  
The basis for yielding smaller particles in higher glycerol loadings was not systematically 
investigated, but it can be supposed that higher-viscosity media would invoke stronger 
shear forces, thus facilitating fragmentation. Hydrodynamic cavitation was also a likely 
contributor, but its effect on downsizing was likely secondary to hydrodynamic shearing in 
view that cavitation is less pronounced in viscous media, which in fact yielded the smaller 
particles. In addition to the fragmentation events, it follows to suppose that nanoparticles, 
once formed, would be less likely to re-associate in glycerol-rich media, as higher 
viscosities would slow Brownian motion. For overlapping double layers, it would follow to 
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also reason that osmotic flow of the denser glycerol-water media would presumably 
separate the near-agglomerated particles more easily
42
. 
In addition to the above, steric and electrokinetic effects were also considered as having 
potentially contributed to the observed particle size distribution, since both are known to 
influence dispersion stabilities. Steric repulsion could not have applied herein, as each 
nano-CLPA surface was solvated with water or glycerol as opposed to large chains such as 
PEG. In contrast, various electrokinetic effects could have resisted re-agglomeration, but 
their relative contribution was difficult to rank, particularly in transcending from water to 
the less understood water-glycerol system. In any case, what is expected was a decrease of 
the dielectric constant in proceeding from water to glycerol-rich media, reflecting a weight-
averaged contribution of both liquids. The near-equivalent hydrogen bonding of water and 
glycerol also implied spatial homogeneity of the weight-averaged dielectric constant, with 
potential enrichment of glycerol, in view of its chelating ability, being conceivable only 
along the immediate nano-CLPA surface. For aqueous-polar organic mixtures, established 
electrokinetic theories are expected to hold true
43
, permitting some analysis as a function of 
the decreased dielectric constant. For instance, the Henry equation as well as measurements 
reported for alumina dispersions in water-glycerol systems
44
 would predict an increased 
magnitude of the zeta potential. Hence, nano-CLPAs placed in glycerol-rich media would 
be expected to take on improved stability. That being said, a decrease of the dielectric 
constant could also conceivably prompt re-agglomeration, as implied by a decreased 
Debye-Hückel screening strength
42
, which would serve to thin the double-layer and permit 
closer approach of dispersed particles. Even so, it was not clear if the double layer 
thickness had dropped beneath the average inter-particle separation in glycerol-rich media. 
Hence, both scenarios could have contributed, or a high zeta potential alone might have 
established a stable dispersion of small nano-CLPAs in 70 wt% glycerol. 
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Figure 3.8: Effect of glycerol incorporation in aqueous homogenization medium on 
nanonization efficiency and nano-particle generation yield. (Albumin CLPA was 
homogenized at 20 krpm, 30 min) 
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Preparation of nano-CLPA for initial in vitro cell internalization studies, described in the 
next chapter, has indirectly led to use of ethanol as homogenization medium. These trials, 
initially intended as disinfection pre-treatment, have posed a plausible alternative to 
aqueous glycerol medium. 
At 70 wt% aqueous ethanol solution the nanonization data has not differed substantially 
from results obtained in double distilled water medium homogenization. On the other hand, 
use of absolute ethanol, while following more or less comparable scale as that of the 
aqueous homogenization in achieved particle size, has resulted in a dramatic increase in 
overall efficiency and much higher precision in resultant nanoparticle size distribution.  
As opposed to the rationale of increased shear forces applied to material due to high 
viscosity of the glycerol containing homogenization medium, herein it appears that the 
induced nanonization yield arises from change in intrinsic mechanical behavior of the 
material, induced by the medium.  Given the specific efficiency of anhydrous ethanol, it 
may be assumed, that the effect of desiccation by highly hygroscopic solvent leads to 
elevation of Tg (glass transition temperature) leading to embrittlement of the material
45
. 
Indeed, even trace amounts of water in pharmaceutical lyophilizates are known to undergo 
much more rapid deterioration due to the strongly plasticizing effect of residual water. In 
short, the highly efficient stabilization of generated nano-particles could be rationalized by 
induced “dryness” of the system. In contrast, the presence of any highly hygroscopic 
solvent like water reduces the kinetic barrier for structural reorganization such as those 
prompted by the temporary separation of inter-particle hydrogen bonds and salt bridges.     
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Figure 3.9: Effect of ethanol incorporation in homogenization medium on nanonization 
efficiency and nano-particle generation yield. (Albumin CLPA was homogenized at 20 
krpm, 30 min) 
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Introduction of both aqueous glycerol solution and ethanol into homogenization medium 
has resolved the overall yield issue encountered in the preliminary work to a large extent. 
The application of each method has separate advantages. While homogenization in glycerol 
medium possesses the benefit of further ease of finer particle size separation through 
centrifugation, lacking in case of ethanol medium. Therefore, glycerol incorporation might 
prove beneficial for applications requiring very high precision of particle size distribution. 
With that in mind, the crude size separation precision of ethanol as homogenization 
medium exceeds that of glycerol even at highest concentrations of the later. 
Furthermore glycerol concentration by itself is a powerful tool in adjustment of particular 
size range for a given CLPA formulation and protein type, which obviously is only 
achieved in ethanol medium by manipulation through homogenization rate and time. 
The most important advantage of ethanol appeared to be the observed preservation of less 
brittle formulations such as dehydrothermally crosslinked and dextran polyaldehyde 
crosslinked CLPL. These softer formulation, would fail under high shear rates (over 9-10 
krpm) applied in aqueous and glycerol incorporated media, which could be directly 
observed by foaming resembling native protein solution property and smeared appearance. 
This effect was most likely unrelated to cavitative damage as described earlier in the text, 
since the behavior occurred to higher degree in glycerol rich media, but rather due to 
intolerable plastic deformation of the material matrix under high shear conditions. This 
resulted in rapid irreversible agglomeration of the large portion of nano-particle content 
generated and generally in significant to complete loss of catalytic activity. The tightened 
matrix of ethanol submerged material, leads to minimization of plastic deformation, 
facilitating brittle fracture therefore preserving the integrity of the material while 
facilitating covalent bond rupture, under greatly decreased shear conditions.    
Further discussion on relationship of synthesis protocol and nanonization efficiency is 
included further in this chapter. 
Both methods require eventual transfer of the nanosized material into an aqueous 
environment for most applications aimed. Complete precipitation out of the medium 
through centrifugation followed by re-suspension in buffers resulted in irreversible 
agglomeration of larger part of formed nanoparticles. Air drying of particles suspended in 
ethanol had the same consequence. As mentioned earlier, filtration was ruled out due to 
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clogging of the membrane once again leading to agglomeration. Therefore, the only 
feasible method appeared to be dialysis against the desired final medium, which has proved 
sufficiently easily applicable, and resulted in successful preservation of nano-particle 
content. Here once again, the use of ethanol as homogenization medium appears beneficial 
due to readier diffusion of ethanol as compared to glycerol, which has required longer 
dialysis times and at least 5 dialysis medium changes. Moreover, for attempted in vitro 
experiments (see Chapter 4.) ethanol medium has also served the sterilization purposes of 
the material prior to incubation with cell culture, only requiring dialysis against sterile PBS 
or cell culture medium.  
 
 
3.4.2.2. Homogenization speed on yield and size reduction efficiency 
 
Just as observed through preliminary screening data homogenization speed forms the main 
size reduction parameter, higher shear rates generating lower size particles, that is, in the 
range prescribed by the CLPA formulation and protein type given. Combined with the 
medium composition variable it was possible to fine tune the desired particle size range at 
high yields.  
Applied in combination with varying medium compositions, lower rates could not be 
efficiently applied to more viscous homogenization medium formulations, due to 
insufficient mixing of the sample at higher viscosity values. 50 wt% and higher glycerol 
concentrations could only be successfully incorporated at speeds of 15 krpm and higher.  
Furthermore homogenization speed of 22 krpm and higher, has been observed to result in 
re-agglomeration of generated nano-particles, even in case of most mechanically stable 
CLPA formulations. 
Figures 3.10-12 represent the effect of homogenization rate on nanonization efficiency in 
protein type specific manner, on albumin, trypsin and Savinase® CLEA (CLEA 
Technologies) examples respectively. 
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Figure 3.10: Effect of homogenization speed on nanonization efficiency of albumin CLPA. 
(homogenized in 30 wt% glycerol for 30 min) 
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Figure 3.11: Effect of homogenization speed on nanonization efficiency of trypsin CLPA. 
(homogenized in 50 wt% glycerol for 30 min) 
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Figure 3.12: Effect of homogenization speed on nanonization efficiency of Savinase® 
CLEA (CLEA Technologies). (Homogenized in 50 wt% glycerol for 30 min) 
 
 
3.4.2.3.  Homogenization time on yield and size reduction efficiency 
 
Nanonization could be achieved after periods as short as 5 min, but in order to achieve size 
distribution homogeneity longer homogenizations times were required. While some 
decrease in overall particle size was observed with increasing homogenization time, in 
glycerol medium homogenizations this parameter is best used to optimize size homogeneity 
quality and overall yield, rather than size fine tuning tool (Figure3.13). All nano-CLPA 
shown bellow were achieved as a result of at least 30 min homogenization, in order to 
minimize the particle distribution error. 
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Figure 3.13: Effect of homogenization speed on nanonization efficiency of albumin CLPA. 
(Homogenized in 30 wt% glycerol at 20 krpm) 
 
In case of ethanol homogenization, homogeneous particle distribution was achieved 
significantly more rapidly (15-20 min) and extended homogenization times were, to some 
extent, utilized to fine tune the desired particle size of a given CLPA formulation. 
 
 
3.4.2.4.  Particle size versus catalytic activity 
 
All data demonstrated versus defined particle size was obtained as a result of repeated 
homogenization in sequence with DLS measurements. The data presented here is gathered 
from repeatable trials, as can be observed from the standard deviation data included.  
Unfortunately this wasn’t always the case, and approach has not always been optimal, re-
agglomeration would occasionally occur upon second or third homogenization, observably 
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related to human error. Furthermore, decrease in reproducibility of resultant catalytic 
activity was observed even where predicted particle size could be established.   
The main factor was observed to be the immersion depth, and particularly location of the 
hole on the homogenization tool with respect to the medium surface (Figure 3.14), of the 
homogenization rode, arranged manually and affecting all formulations independent of 
protocol and conditions, therefore rendering the process repeatability highly dependent on 
gathered experience applied within the limits of human error, rather than engineering 
controlled. This mainly reflected on unanticipated increase in homogenization medium 
temperature.  
 
 
Figure 3.14: Visualization of sample placement prior to homogenization 
 
Raise in temperature of the medium during homogenization was a factor not fully 
investigated. Main controllable parameters were medium composition, where most viscous 
mediums led to highest increase, and homogenization rate, where temperature raise would 
increase with increasing rate. The temperature rise fluctuations could also be observed in 
case of any specific CLPA formulation. The general temperature increase prescribed by 
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these parameters was up to 30-50 ˚C with the device operated at laboratory temperature 
conditions (20 ˚C).   
Significant rapid increase in temperature up to 70-90 ˚C, was occasionally observed 
unrelated to the intrinsic material and homogenization medium formulations. The resultant 
samples of different formulations were analyzed and while the nanonization efficiency 
would generally correspond to the given formulation and protocol, the dramatic decrease in 
catalytic activity (results not shown, due to lack of systematic appearance of the issue). 
Obviously, on formulations described earlier as more susceptible to plastic deformations, 
were affected to greater extent, nevertheless unlike the described earlier effect of glycerol 
and ethanol media incorporation, in this case significant loss of catalytic activity was 
general for all formulations, independent of the protocol.  
It can be assumed, that slight changes in positioning of the rotor tool components with 
respect to medium surface has led to alteration of flow character. The observed increase in 
turbidity of the sample, pointing to increased air bubble incorporation within the medium, 
could lead to conclude a sudden cavitation number increase, in which case further increase 
in hydrodynamic cavitation portion would be expected with increasing temperature.  
These observations occurred under limitations of laboratory scale design, and could be 
overcome with development of a fully automated system, in order to eliminate the human 
error factor and optimize the reproducibility. A system equipped with thermostat controlled 
cooling jacket could prove further beneficial for both repeatability improvement and 
preservation of integrity in certain CLPA formulations. 
Observed on Figure 3.15 is a relationship of particle size to catalytic activity of sub-optimal 
formulation of trypsin CLPA (excessive crosslinking degree). This example is chosen here, 
since the highly brittle nature of the formulation allowed easily adjustable very precise 
nano-particle size generation. As has been shown in the preliminary study discussion, 
altering of the diffusion limitation in large substrate involving catalysis significantly affects 
the resultant activity. 
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Figure 3.15: Effect of particle size on catalytic activity of trypsin CLPA. (sub-optimally 
formulated CLPA) 
 
The similar pattern was observed on the example of the Savinase® CLEA (CLEA 
Technologies) (Figure 3.16), demonstrating generality of this approach. The significant gap 
between macroscopic and sub-micron size particle catalytic activity is observed, followed 
by further gradual change amongst different size fractions.    
 
82 
 
 
Figure 3.16: Effect of particle size on catalytic activity of Savinase® CLEA (CLEA 
Technologies).  
 
 
 
3.4.3. Optimization of CLPA synthesis steps in terms of nanonization yield, 
size and final product catalytic activity  
 
 
CLPA preparation was influential in terms of downsizing efficiency, as the particular 
manipulations used to enforce aggregation ultimately defined the packing and crosslinking 
densities of the protein aggregates. Effective packing as well as sufficient crosslinking 
served to “stiffen” the crosslinked precursor, enabling size-reduction at length scales where 
soft materials generally become self-plasticizing and increasingly difficult to downsize. 
83 
 
Furthermore, the catalytic activity of downsized material, while generally increased to the 
extent defined by the protocol and resultant particle size, clearly bared the pattern 
established of its corresponding macroscopic precursor.   
This trend is nicely demonstrated on the model of trypsin nano-CLPA (Figure 3.17), which 
follows the pattern described in Chapter 2. Here despite much more efficient size reduction 
of glutaraldehyde crosslinked material, catalytic activity of dehydrothermally crosslinked 
CLPA still exceeds, although to somewhat less ratio degree than that of macroscopic 
precursors. This effect can be attributed both to the difference in aggregation and 
lyophilization techniques as well as potentially activity degrading effect of glutaraldehyde 
crosslinking. Furthermore, increase of catalytic activity of dehydrothermally crosslinked 
nano-CLPA, as compared to its macroscopic precursor, demonstrates that increase in the 
surface area is a separate parameter acting additionally to the improved accessibility 
provided by intrinsic high porosity of the material, further decreasing diffusion limitations 
on the nanoscale.   
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Figure 3.17: Comparison of chemically and dehydrothermally crosslinked CLPA 
nanonization results 
 
This method, although highly efficient, is not exploited in the following nanonization 
studies, for the same reasons earlier mentioned in favor of increased catalytic activity: 
fewer crosslink formation and higher porosity is leading to a very soft material which is 
also less mechanically stable, compared to chemically crosslinked CLPA. Homogenization 
in absolute ethanol was employed, preventing loss of catalytic activity due to material 
deformation, but nano-particle size generation capacity was rather limited. Instead CLPL 
formulations described in Chapter 2, were preferred due to chemical crosslinking induced 
rigidity, while still preserving increased activity associated with high porosity prescribed by 
the precursor lyophilizate.    
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3.4.3.1.  Effect of precursor solution conditions  
 
No independent relevance could be established between nano-particle generation and 
precursor solution, rather it was realized through crosslinking efficiency determined by the 
precursor solution.    
In terms of catalytic activity, the effect trend demonstrated on macroscopic precursor can 
be obviously observed herein with 3-4 fold increase implemented by size reduction. 
 
Figure 3.18: Precursor solution effect on 300 nm nano-CLPA catalytic activity. Trypsin 
CLPA (aggregated in acetone, glutaraldehyde crosslinked)  
 
3.4.3.2. Effect of aggregation method  
 
While not confirmed directly, it could be supposed that among the available protein 
aggregation methods, those leading to greater inter-protein packing or ordering would 
better facilitate nanonization, much like crystalline material is more easily ground 
compared to amorphous forms. For example, trypsin CLPA of otherwise same protocol 
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obtained from aggregation with saturated ammonium sulfate and 2-propanol, have led to 
readier downsizing of the later  
That being said, as discussed in Chapter 2., aggregation method has incremental effect on 
final product catalytic activity. This and facilitation of efficient crosslinking were 
predominant parameters of choice in optimizing nano-CLPA formulation protocol, rather 
than as the particle size distribution fine tuning tool. The results of nano-CLPA analysis 
were found to parallel to those of CLPA with respect to aggregation method versus relative 
activity.  
 
 
Figure 3.19: Aggregation medium effect on 300 nm nano-CLPA catalytic activity. Trypsin 
CLPA (glutaraldehyde crosslinked) 
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As mentioned earlier, chemically crosslinked CLPL provided much improved nanonization 
capacity, as compared to dehydrothermally crosslinked lyophilizates. Nano-CLPL as 
observed from its dextran polyaldehyde crosslinked precursor earlier resulted in plausible 
activity yields, when combined with optimum starting solution conditions (example in the 
next section). The method was further supported by 100% synthesis yield.  
 
 
3.4.3.3.  Effect of crosslinking method  
 
Examples of most chemically crosslinked CLPA, assuming formulations providing 
sufficient covalent crosslinking, which blocks any possibility of inter-protein reorganization 
of shear-stressed material, enforcing bouts of catastrophic mechanical failure as opposed to 
gradual stress-to-strain changes. Macroscopically speaking, the covalent crosslinking of 
densely-packed aggregates paralleled the effects of metal embrittlement, as evidenced by 
lack of malleable deformation, namely, CLPA smearing, in favor of brittle-fracture-like 
fragmentation.  
The fact that catalytic activity of nano-CLPA compared to corresponding precursor CLPA, 
while numerically increased in statistically significant fashion, posses almost identical 
trends, further supports the above claiming, showing that the only effect implemented by 
downsizing treatment is the reduction of diffusion limitation catalytic activity. This trend is 
demonstrated on the same CLPA formulations provided in Chapter 2. In comparison of 
crosslinking reagent pH effect (Figures 3.20 and 3.21) 
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Figure 3.20: Crosslinking reagent (glutaraldehyde) pH effect on 300 nm nano-CLPA 
catalytic activity. Trypsin CLPA (pH 4.5 precursor solution, aggregated in 2-propanol) 
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Figure 3.21: Crosslinking reagent (dextran polyaldehyde) pH effect on 300 nm nano-CLPA 
catalytic activity. Trypsin CLPA (pH 4.5 precursor solution, aggregated in 2-propanol) 
 
As it has been demonstrated earlier, during homogenization medium discussion, particular 
formulations do not withstand high shear rates in high viscosity medium, namely aqueous 
glycerol solutions. These include much softer formulations: dehydrothermally crosslinked 
and dextran polyaldehyde crosslinked lyophilizates. This does not apply to glutaraldehyde 
crosslinked CLPL, which appears to perform as a robust material closely resembling CLPA 
formulations, but the results for these formulations are not presented herein, due to 
unsuitability of this formulation in case of protease examples demonstrated here. Efficient 
downsizing procedure was achieved through absolute ethanol homogenization medium 
employment for dextran polyaldehyde CLPL, as described earlier, yet while readily 
nanosized, no particles under 200 nm could be generated in these formulations. As can be 
observed from Figure 3.22, this did not cause a serious concern, since the catalytic activity 
fluctuation appears to be greatly reduced between 300 and 200 nm particles.  
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This trend could be explained by two scenarios, the plausible case being that at around 300 
nm catalyst approaches, reaction limited rates rather than diffusion limited. Unfortunately, 
this could not be verified, since kinetic studies, initially being within ambition of this work, 
could not be conducted due to technical difficulties. And will present the main subject of 
further research on the topic.  
Less desirable scenario involves incremental deformation under highest shear rates leading 
to some degradation of activity expected from a smaller size particle. 
 
Figure 3.22: Effect of particle size on catalytic activity of trypsin CLPL  
 
 
3.4.3.4.  Effect of crosslinking degree 
 
Given the main rationale, that increased robustness implemented by covalent crosslinking 
facilitates brittle fracture of CLPA in homogenization medium, it is not surprising to 
observe that higher crosslinking degree would provide lower nano-particle size under same 
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downsizing conditions (Figure 3.23). Nevertheless, as described in Chapter 2., excessive 
crosslinking dramatically affects the CLPA activity, which is directly reflected on 
corresponding nano-CLPA formulations and must be optimized with caution (Figure 2.24). 
Data for 1. and 2. crosslinking formulations could not be obtained, due to inability to 
downsize these softer materials to the common scale with the rest of the formulations.    
 
Figure 3.23: Effect of precursor CLPA crosslinking degree on nanonization efficiency. 
(Albumin CLPA homogenized in 50 wt% glycerol at 20 krpm) 
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Figure 3.24: Effect of precursor CLPA crosslinking degree on catalytic activity of 300nm 
trypsin nano-CLPA.  
 
 
 
3.4.4. Stability of nano-CLPA 
 
 
3.4.4.1. Comparison of operational and hydrolytic stability of CLPA and 
nano-CLPA 
 
CLPA/CLPL synthesized in house and generated nano formulations have been tested for 
operational stability in a manner that would facilitate comparison to CLEA data provided 
by Sheldon et al
46
. The results for both macroscopic and nano materials have been shown 
comparable. These experiments were performed on macroscopic and 300 nm trypsin 
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formulations generally described as optimized in this Chapter, namely optimal formulations 
of glutaraldehyde, dextran polyaldehyde crosslinked CLPA and dextran polyaldehyde 
crosslinked CLPL.  
It was observed that nano-CLPA bared the continued activity of the precursor CLPA, and is 
suitable for continuous processes. CLPA and nano-CLPA incubated in PBS under mild 
agitation at 50 ˚C for 1-14 days resulted in identical residual catalytic activity (results not 
shown). 
Furthermore, recyclability of nano-CLPA was realized by repeatedly dialyzing of the 
particles out of previous reaction medium. 10 consequent trials have led to statistically 
insignificant alterations in catalytic activity results. This result was not surprising based on 
the established reusability of CLPA precursors mentioned in the literature
46
. Successful 
repeated dialysis, on the other hand, has provided evidence of suspension stability. 
 
 
3.4.4.2.  Storage stability 
 
Storage stability of CLPA formulations is conventionally accepted, stability of nano-CLPA 
suspensions overtime, in different 2.5 mg/ml potassium chloride containing aqueous 
glycerol concentrations, absolute ethanol and PBS buffer was established here. Suspensions 
left to sit at room temperature and 4 ˚C for as long as 4 month were all readily re-suspended 
upon agitation. DLS measurements have shown increase hydrodynamic diameter in 0-30 
wt% glycerol solution with lowest concentrations approaching 1 micron, after periods as 
short as a week. 40-70 wt% glycerol solutions, absolute ethanol and PBS buffer 
suspensions have retained the initial particle size upon the whole incubation period. 
Stabilization of nano-particles in high glycerol concentrations and absolute ethanol have 
been discussed earlier. So was the effect of salts in arresting re-agglomeration of nano-
particles in homogenization medium, apparently this effect upon prolonged periods of 
incubation required higher ionic strength, such as provided by the isotonic PBS solution, in 
order to establish sufficient zeta potential of suspended particles.    
No evidence was obtained on storage stability exceeding 4 month period, but eventual 
irreversible agglomeration at some point is suspected for all above medium compositions.  
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Surprisingly enough, given the complexity and unpredictability of freezing process 
conditions, nano-CLPA lyophilized in PBS buffer, upon re-suspension formed the same  
nano-particle distribution suspension achieved in a matter of seconds, as verified by DLS 
measurement (results no shown). This discovery provides a much more convenient storage 
alternative to suspension. Furthermore, for potential synthesis applications in various 
organic media, this could serve as an alternative to dialysis, particularly with less water 
miscible solvents.   
 
 
 
3.4.5. Applicability of the scale up process 
 
 
The applicability of scale up process was assessed using industrial grade protease mixture 
Palkofeed (Maps Enzymes) in a pilot scale trial. Aggregation and crosslinking steps were 
performed in the same reactor started by gradually pouring Palkofeed solution into 35L 
volume aggregation medium. The obtained CLPA was subsequently dried and ground using 
Gelimat compounder with addition of potassium chloride, as performed in the initial trials. 
The same synthesis formulation applied Palkofeed CLPA synthesis was performed on 
laboratory scale, and homogenized under same shear rates as Gelimat compounder 
provided, in order to compare the efficiencies of different scales. As can be observed from 
Figure 3.25 the results appeared closely comparable.    
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Figure 3.25: Comparison of scale up and laboratory scale nano-CLPA synthesis efficiency 
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4. Nano/Micro-CLEA Formulations for Potential Biomedical Applications 
 
 
 
 
4.1. Introduction and Rationale  
 
 
 
The aim of this chapter is to introduce of nano-CLPA as potential alternatives to 
commercially available conventional formulations. 
Examples of generally used products include antimicrobial powders, wound healing aids 
and digestive aids
31,47
. Plausible alternative to these products could be formed by lysozyme 
CLPA, lysozyme/hemoglobin nano-CLPA and a complex of hydrolytic enzyme CLPA 
respectively. 
Hemoglobin based oxygen carriers (HBOC) provide a more specific example. Many 
formulations have been attempted in the field but none are applicable yet. Along with 
optimization of oxygen affinity and release, renal filtration in case of particles under 
100nm, and hepatic/spleen clearance for larger particles is one of the main concerns. This 
leads to short half life of the particles, and toxicity
48,49
. This problem could potentially be 
addressed by hemoglobin nano-CLPA, by maintained particles around 150nm.  
Another example is an alternative formulation for enzyme replacement therapy approach to 
lysosomal storage disorders
50
, in form of long-term therapy, stable enzyme powders with 
rapid mass transfer traits. 
Herein, feasibility of co-aggregate complex formulations is represented on the example of 
hemoglobin/lysozyme nano-CLPA. Furthermore, internalization studies are performed on 
generated albumin and alpha-galactosidase nano-CLPA, later as a representative of 
lysozomal deficient enzymes. This preliminary work merely induces a discussion of 
potential utilization of nano-CLPA as a systemic therapeutic.  
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4.2. Materials 
 
 
 
Alpha galactosidase was obtained from Sigma Aldrich. α-Galactosidase from green coffee 
beans, ammonium sulfate suspension, ≥9 units/mg protein 
Other proteins were obtained as described in Chapter 2. 
Trypsin solution (Trypsin-EDTA (0.05%), phenol red), Dulbecco’s modified Eagle medium 
(DMEM) (+4.5g/L D-Glucose, + L-Glutamine, - Pyruvate, phenol red), heat inactivated 
Fetal Bovine Serum (FBS), antibiotic solution (Penicillin-Streptomycin; 10,000 U/mL) 
were obtained from Gibco®.  
Dulbecco’s modified Eagle medium (DMEM) (+4.5g/L D-Glucose, + L-Glutamine, - 
Pyruvate, - phenol red) was obtained from Pan Biotech GmbH. 
Human Epithelial Cervix Adenocarcinoma (HeLa; ATCC
®
 Number: CCL-2
™)
, Human 
Epithelial Colorectal Carcinoma (HCT 116; ATCC
®
 Number: CCL-247™), Human 
Embryonic Kidney (HEK-293; ATCC
®
 Number:  CRL-1573™)  and Mouse Embryonic 
Fibroblast (NIH/3T3; ATCC
®
 Number: CRL-1658™) cell lines were kindly donated by Dr 
Batu Erman of Sabanci University, Biological Sciences and Bioengineering Program. 
All other reagents were obtained from commercial suppliers as analytical grade and were 
used without further purification. 
 
 
 
4.3. Methods 
 
 
 
4.3.1. Synthesis of albumin, lysozyme, hemoglobin, lysozyme/hemoglobin co-
aggregate and alpha-galactosidase CLPA 
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4.3.1.1.  Precursor protein solutions 
 
Protein solutions described in this chapter were generally of the following composition: 
 
Protein(s) 
Concentration 
(mg/ml) 
Solution composition pH 
Hemoglobin 50 
100mM potassium chloride in 10mM sodium 
acetate buffer 
5,6 
Lysozyme 100 
100mM potassium chloride in 10mM sodium 
acetate buffer 
5,6 
 
Hemoglobin/ 
Lysozyme 
50/50 
100mM potassium chloride in 10mM sodium 
acetate buffer 
5,6 
 
Albumin 100-200 100mM sodium phosphate buffer 
7,4 
 
 
 
4.3.1.2.  CLPA synthesis and nano-particle generation 
 
Precursor CLPA formulations were synthesized as described in Chapter 2. 
Alpha–galactosidase, obtained in the form of suspension in ammonium sulfate solution, 
was an exception. Precursor solution and further aggregation procedures have not been 
performed and dialysis was not attempted; crosslinking was performed directly in the 
commercially obtained suspension medium. 
Size reduction was performed via homogenization as described in Chapter 3, the 
corresponding procedures are specified in the text. 
Modification of CLPA with PEG was realized through addition of 1:1 and 1:10 (protein: 
PEG) molar ratio of monofuctional PEG amine (600 MW) or aqueous solution of 
bifuctional PEG amine (1900 MW) into unreduced crosslinking medium. Reaction was 
conducted on the resultant mixture for 30 min under homogenization conditions at 10 krpm. 
The suspension was thereafter reduced by incubation with 0.1 % sodium borohydride 
solution for 30 min at mild agitation. Suspension was diluted with glycerol solution, to 
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obtain the desired glycerol wt% of the medium and further size optimization was performed 
where needed, through additional homogenization.  
 
 
 
4.3.2. In Vitro Cell Culture Study 
 
 
4.3.2.1.  Preparation of nano-CLPA for cell culture incubation 
 
Nano-CLPA suspension of optimized size has been modified with dansyl chloride, for 
visualization purposes in florescent microscopy experiments, through the following 
procedure: 
0.6 ml of 2.5mg/ml nano-CLPA suspension obtained after homogenization was diluted with 
0.8 ml pH 9.2 0.1M carbonate buffer and incubated for 1 hour at room temperature with 
agitation (550 rpm) upon addition of freshly prepared 0.1ml 3mg/ml dansyl 
chloride/dimethyl formamide solution. 
Upon dansylation the labeled nano-CLPA samples were transferred into 1.5 ml eppendorf 
tubes with the dialysis membrane replacing the top of the tube cap, tubes were further 
secured with parafilm tape to avoid any leakage. All samples prepared as described were 
dialyzed against pH 7.4 PBS buffer, with constant agitation, for the period of 6 hours, 
repeated 4 times. 
Material disinfection has been performed by dialysis against 70 wt% ethanol solution 
containing 5 wt% sucrose and subsequently dialyzed against sterile PBS, for the period of 6 
hours, repeated 3 times. Buffer exchanges were performed in the laminar flow hood. All 
subsequent dilutions were performed with sterile PBS. 
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4.3.2.2.  Cell culture preparation 
 
HeLa, HCT116, HEK-293, NIH/3T3 cell lines were maintained in complete DMEM - 
supplemented with 10% heat inactivated fetal bovine serum, 100 unit/ml penicillin and 100 
unit/ml streptomycin. For cell viability assays phenol red free DMEM was used.  
 
 
4.3.2.3.  Internalization/localization study 
 
HeLa and NIH3T3 cells were cultured on 6-well plates at a density of 4x10
4
 cells per well 
with unmodified cover slips placed on the bottom of each well in complete DMEM and 
incubated at 37 ºC in a tissue culture incubator under a 5% CO2 atmosphere. Internalization 
trials were performed upon 24 hour incubation. 
 
Lysosome staining   
Where applicable, lysosome staining was performed using Cell Navigator™ Lysosome 
Staining Kit (Red Fluorescence), reagent was prepared as prescribed in the manufacturer 
protocol (AAT Bioquest®, Inc). Medium was removed and replaced with 1ml medium 
supplemented with 10 v% of the fluorescent reagent and incubated for 30min in tissue 
culture incubator. Upon incubation, medium was removed and wells were washed thrice 
with warm PBS buffer, 2 ml of complete DMEM was replaced.  
 
Nano-CLPA internalization 
20 µl 1mg/ml Nano-CLPA suspension were directly introduced into 2ml cell culture 
medium and incubated for 3 h, if not stated differently in the text. Upon incubation, 
medium was removed and wells were washed thrice with warm PBS buffer. After the last 
wash, cells were fixed using 3% paraformaldehyde solution, washed thrice with PBS and 
placed on the slide. 
Subsequent analysis was conducted using Zeiss confocal microscope. Visualization of 
dansylated nano-particles was conducted by excitation with 405nm laser and lysosomal 
staining dye by excitation with 561 nm laser. All images compared were obtained under 
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same conditions and images processed identically. Image processing was performed using 
Zeiss software. 
 
 
4.3.2.4.  Viability upon internalization  
 
HeLa, HCT116, HEK-293, NIH/3T3 cells were cultured on 96 well plates at a density of 
4x10
3
 cells per well in complete DMEM. Nano-particle incubation was performed upon 24 
hour incubation for HeLa and HCT116 cell cultures and upon 36 hour incubation for HEK-
293 and NIH/3T3.  
Nano-CLPA suspensions were directly delivered into the cell culture medium at 
corresponding dilution in 20 µl aliquots per 180 µl medium and incubated for 3 hours. 
Upon incubation, medium was removed and wells were carefully washed thrice with warm 
PBS buffer. After washing, 100 µl of phenol red complete DMEM medium is replaced.  
Control wells were supplemented with 20 µl aliquots of PBS. 
MTT test was performed at 0, 24 and 48 hour time points upon nano-particle incubation. 
10 µl of MTT labeling reagent was added and incubated for 4 hours in tissue culture 
incubator. Upon incubation 100 µl MTT solubilizing solution was added and incubated 
overnight at 37 ˚C. Absorption values were measured at 570 nm using a reference 
wavelength of 665nm in accordance with the Roche Applied Science Cell Proliferation Kit 
I (MTT) protocol (Roche Applied Science; apoptosis, cell death and cell proliferation 3d 
edition, 85-86). 
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4.3.3. Characterization 
 
 
4.3.3.1. Relative bioactivity assays 
 
Lysozyme 
Assay method 1. The assay is based on lysozyme catalyzed hydrolysis of synthetic 
substrate, 4-Methylumbelliferyl β-D-N,N′,N′′-triacetylchitotrioside ((GlcNAc)4-MeU). 
Hydrolytically liberated MeU amount is detected fluorimetrically upon 360nm excitation at 
455 nm emission.  
The reaction was conducted as follow: 10 µl 5x10
-4
 M reagent solution was added into 190 
µl 1 mg/ml lysozyme solution or nano-CLPA suspension in 100mM potassium chloride in 
10mM acetate buffer solution. Reaction was conducted for 30 min at 37 ˚C under 450 rpm 
agitation. Reaction was terminated with pH 11 buffer and fluorimetrically measured at λex 
= 360 nm, λemm= 455 nm. The established pH was established to favor fluorescent anionic 
form of MeU.  
Native protein solution measurements were assigned a value of 100% and CLPA 
measurements were calculated relative to this value. 
Assay Method 2. Micrococcus luteus cell wall digestion assay was performed as described 
in Chapter 2.  
 
Bovine Serum Hemoglobin assay was performed as described in Chapter 2. 
 
Alpha-galactosidase 
The assay is based on alpha-galactosidase catalyzed hydrolysis of synthetic substrate, p-
Nitrophenyl α-D-Galactopyranoside Solution (PNP-Gal). Hydrolytically liberated p-
nitrophenol amount is detected spectrophotometrically at A405nm. The reaction was 
conducted as follow: 200 µl 10 mM reagent solution and 100 µl 1 mg/ml alpha-
galactosidase solution or nano-CLPA suspension was added to 700 µl reaction buffer in 
80mM potassium phosphate pH 6.5 buffer. Reaction was conducted for 30 min at 25 ˚C 
under 450 rpm agitation. Reaction was terminated by addition of 9.8 pH buffer. Amount of 
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liberated p-nitrophenol was assessed spectrophotometrically at A405nm . Native protein 
solution measurements were assigned a value of 100% and CLPA measurements were 
calculated relative to this value. 
 
 
 
4.4. Results and Discussion 
 
 
 
4.4.1. Lysozyme, hemoglobin and lysozyme/hemoglobin co-aggregate nano-
CLPA  
 
 
4.4.1.1.  Nano-CLPA optimization  
 
Hemoglobin solutions were readily aggregated in all attempted media, generally described 
in Chapter 2. That being said significant loss of catalytic activity appeared in most of the 
formulations, with an exception of ammonium sulfate aggregation provided CLPA.  
Crosslinking was readily achieved through all conventionally described techniques; Figure 
4.1 represents crosslinking method effect on catalytic activity of hemoglobin. Herein, 
hemoglobin is assessed in terms of its oxidase catalytic activity.  
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Figure 4.1: Crosslinking method effect on 200 nm hemoglobin nano-CLPA catalytic 
activity.  
 
Downsizing procedures were conducted without apparent structural damage, as would be 
expected from brittle appearance of obtained CLPA. That being said, gradual particle size 
adjustment has posed a challenge, since CLPA homogenized even in low concentrations 
aided rapid decrease in size. The issue was not successfully addressed herein.  
Given the particularly small molecular weight of substrates in the applied activity assay, the 
small fluctuations between different size catalyst is not surprising (Figure 4.2)  
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Figure 4.2: Effect of homogenization speed on size reduction and resultant catalytic activity 
of dextran polyaldehyde crosslinked hemoglobin CLPA. (CLPA was homogenized in 30 
wt% glycerol for 30 min) 
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Ethanol, acetone and ammonium sulfate has appeared highly efficient for lysozyme 
precipitations, but some degradation of catalytic activity has been observed in ethanol and 
acetone aggregated formulation. Ammonium sulfate aggregation has been established 
optimum and was utilized thereof.   
Figure 4.3 presents crosslinking method effect on lysozyme nano-CLPA catalytic activity. 
Remarkably, as has also been noted in the initial studies, generally highly efficient 
dehydrothermal crosslinking method has yielded the lowest activity in case of lysozyme 
CLPA. Apparent much lower crosslinking degree of CLPA formulation was noted, both 
from much softer appearance of lysozyme CLPA, and from qualitatively observed milder 
fluctuations in amideI/amideII bands upon FTIR analysis (data not shown) for all obtained 
crosslinking formulations, as compared to other attempted proteins. Given the generally 
lower crosslinking capacity of the material, it could be rationalized that very few crosslinks 
were formed upon dehydrothermal crosslinking, therefore avoiding the earlier discussed 
thermodynamic constraint, theorized to have caused increase in catalytic activity, with 
respect to the native enzyme.     
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Figure 4.3: Crosslinking method effect on 150 nm lysozyme nano-CLPA catalytic activity  
 
All formulations of lysozyme CLPA appeared particularly challenging in terms of stability 
during homogenization in high concentrations of glycerol, leading to obvious extensive 
structural damage. This could be attributed to presumably lower crosslinking degree 
achieved through conventional crosslinking methods, as could be visualized by the 
relatively soft appearance. Material had to be mechanically ground with 1:1 weight of 
potassium chloride prior to transfer into glycerol containing medium, in order to avoid 
clogging of homogenizer tool. Nevertheless, successful size reduction yield could be 
achieved at 30 wt% glycerol medium (Figure 4.4), with plausible catalytic activity yields. 
Since, this study has been conducted way before discovery of absolute ethanol alternative 
as a homogenization medium, the corresponding efficiency is not provided herein. It can be 
rationalized that given its performance on softer materials, discussed in Chapter 3., this 
alternative would be successfully applied here, with potential further increase in catalytic 
activity of the formed nano-particles.  
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Figure 4.4: Effect of homogenization speed on size reduction and resultant catalytic activity 
of dextran polyaldehyde crosslinked lysozyme CLPA. (CLPA was homogenized in 30 wt% 
glycerol for 30 min) 
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Lysozyme  nano-CLPA has provided a nice model for demonstration of substrate size and 
catalyst size relationship. The two substrates chosen herein, are posing two extremes in 
size, first: low molecular weight, synthetic substrate and the micron scale natural substrate.  
The predicted slight fluctuations in low molecular weight substrate and gradual increase in 
size dependant manner in case of large substrate can be observed on Figure 4.5. 
Much higher affinity of lysozyme nano-CLPA to its natural substrate could also be noted 
from the provided results. 
 
Figure 4.5: Assessment of substrate size versus catalyst particle size relationship on model 
of dextran polyaldehyde crosslinked lysozyme CLPA. Method 1.: Fluorimetric analysis of 
small substrate degradation; Method 2.: Optical density detection of bacterial wall 
degradation. (please see Methods section for detail) 
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4.4.1.2.  Co-aggregate nano-CLPA 
 
Given the general compatibility of precursor CLPA techniques developed separately for 
both proteins, co-aggregates and subsequent crosslinking procedure were easily achieved. 
Dextran polyaldehyde was chosen as crosslinking reagent for these formulations, as to 
benefit lysozyme catalytic activity. As observed from Figure 4.6, the given downsizing 
protocol yielded an average comparable particle size in hemoglobin, lysozyme and 
hemoglobin/lysozyme co-aggregate formulations. The retention of CLPA formulation 
dictated catalytic activity is also observed. The slight increase in lysozyme catalytic activity 
of hemoglobin/lysozyme co-aggregate nano-CLPA could be noted, and might be explained 
by more efficient preservation of lysozyme CLPA fraction during homogenization 
procedure in this case. Potentially higher crosslinking degree provided by supplementation 
of juxtaposed functional groups due to hemoglobin incorporation can be considered the first 
plausible factor. Furthermore, stabilization of proteins in solution by addition of another 
globular protein is a well established technique.      
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Figure 4.6: Comparison of hemoglobin, lysozyme and hemoglobin/lysozyme CLPA size 
reduction and resultant activity trends 
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4.4.2. in vitro internalization study on the model of albumin and alpa-
galactosidase nano-CLPA  
 
 
Due to rather limited amounts of available alpha-galactosidase stock most of the 
parameters, namely, CLPA protocol, surface modification and particle size, in this study 
had to be assessed through albumin nano-CLPA internalization. Only one formulation of 
alpha-galactosidase could be assessed which was utilized through the effect of particle size 
concentration – cell viability relationship. 
 
 
4.4.2.1.  Nano-CLPA optimization 
 
Albumin nano-CLPA particle size optimization was performed via general techniques 
described in Chapter 3. Higher glycerol concentrations (50-70%) were employed in order to 
ensure maximum size distribution homogeneity. Samples were homogenized at 
approximate conditions prescribed to achieve a given particle size, analyzed with DLS and 
further homogenized at modified speed/time in order to obtain the desired nano-CLPA size 
with minimum particle size distribution error.  The error up to 40 nm has been tolerated.  
Two alpha-galactosidase nano-CLPA formulations were generated and assessed using the 
same CLPA formulation: both brought to 400 nm particle size through 50 wt% glycerol and 
absolute ethanol medium homogenization. Homogenization modes employed here proved 
readily applicable on alpha-galactosidase CLPA formulation.  
50 wt% glycerol and absolute ethanol homogenized alpha-galactosidase nano-CLPA 
catalytic activity was assessed, relative to native enzyme solution, yielding 173% (±8) and 
198% (±7) relative activity, respectively. 
All nano-CLPA samples have been modified with dansyl chloride for further visualization 
purposes. It has been observed that both modification of precursor CLEA material and final 
size nano-CLEA material results in efficient and equivalent modification extent (results not 
shown). All data shown herein is acquired from samples modified post-homogenization 
procedure.  
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 Since nano-CLPA formulations have been prepared in either glycerol or ethanol medium, 
particles purposed for internalization experiments had to be re-suspended in PBS. Dialysis 
has proved a viable technique, with the nano-particle content completely preserved. DLS 
and SEM analysis has been performed on each sample to verify the retained nano-particle 
composition prior to internalization experiments. 
Material disinfection, after homogenization in aqueous glycerol medium, has been 
performed by dialysis against 70 wt% ethanol solution containing 5 wt% sucrose. Sucrose 
was incorporated in order to prevent potential agglomeration of nano-particles. After 
ethanol treatment samples were dialyzed against sterile PBS buffer, buffer exchange was 
performed inside the laminar flow hood, and further introduced into cell culture upon 
protocol prescribed dilution with the same buffer. Samples homogenized in absolute 
ethanol medium were directly dialyzed against sterile PBS buffer, not requiring disinfection 
step. 
Although further disinfection using UV radiation has been avoided in order to preserve the 
fluorophore degradation, ethanol disinfection has been found to be sufficient. Even 
throughout prolonged trials (up to 4 days) in antibiotic free medium, no contamination has 
been observed upon particle incubation (results not shown). 
The overall preparation procedures proved reliable for all nano-CLPA formulations and 
appeared rather user friendly. 
 
 
4.4.2.2.  Cell internalization pattern as a function of CLPA synthesis 
method and nano-CLPA generation protocol 
 
General cell internalization trends of nano-particles have been assessed on HeLa cell line. 
Results did not provide sufficient resolution to conclude effect of variable parameters 
quantitatively, but appear sufficient to raise a preliminary discussion.  
 
Incubation time 
Rapid internalization of glutaraldehyde crosslinked 400 nm sized albumin nano-CLPA can 
be observed on Figure 4.7, throughout 0.5-6 hour incubation periods. Some internalization 
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could be observed upon incubation period as short as 30 min (b), followed by gradual 
increase at prolonged periods, as could be visualized through increase in fluorescence 
intensity. 
 
 
a) Control 
 
 
b) 0.5 h 
 
 
c) 1 h 
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d) 2h 
 
 
e) 3h 
 
 
f) 4h 
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g) 6h 
Figure 4.7: Internalization upon incubation with albumin nano-CLPA. HeLa cell culture 
(glutaraldehyde crosslinked, homogenized in glycerol medium to establish size of 400 nm 
particle size) 
 
Co-localization analysis was performed using CoLocalizer Pro 1.0 software and Manders 
Overlap Coefficient (MOC) was used to estimate the degree of colocalization. Analysis was 
performed on the image corresponding to 6 hour incubation of nano-CLPA. 68.4% overlap 
of dansylated particles with lysozomal dye was detected (Figure 4.8).  
The localization of engulfed particles was suspected to be dominantly located in lysosomes. 
Endocytosis of nano-particles through phagocytic and else pathways, both generally result 
in compartmentalization in lysosome
51
. 
 
 
Figure 4.8: Co-localization analysis illustration upon incubation with albumin nano-CLPA 
and lysosomal staining dye. HeLa cell culture 
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Nano-CLPA particle size 
Figure 4.9 demonstrates internalization of different particle size albumin nano-CLPA. 
Interestingly enough, no internalization is observed of 100 nm particles. Behavior of nano-
CLPA, otherwise shown stable in PBS, was not investigated for FBS containing DMEM 
environment. It could be suspected, that irreversible re-agglomeration of higher surface 
area particles occurs rapidly preventing cell internalization. It could otherwise be explained 
by ability of smaller sized particles to escape the compartment, which was precedent 
through pumping out
52
.  
 
 
Figure 4.9: Size dependant internalization of albumin nano-particles. HeLa cell culture 
 
Nano-CLPA surface modification 
Modification of albumin nano-CLPA with monofunctional PEG amine 600, appeared to 
only slightly alter internalization, as monitored by fluorescence intensity. Some relative 
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decrease in intensity can be observed in case of higher PEG amine surface density, which 
could be readily explained by increase in overall hydrofobicity of the surface.   
Modification with bifunctional PEG amine 1900, on the other hand, resulted in untraceable 
internalization at low PEG amine surface area, and much improved at higher PEG amine 
amounts. It could be rationalized, that suboptimal conformation of longer PEG amine chain 
on the surface due to lack of steric constraint took place in the case of low polymer 
distribution over particle surface, which was optimized by increase in the amount of the 
later. Internalization of the described particles is visualized on Figure 4.10. Furthermore, 
the comparable pattern can be observed upon incubation of the same particles in NIH/3T3 
cell culture (Figure 4.11), therefore providing generality to the above observation. 
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Figure 4.10: Internalization of PEGilated albumin nano-CLPA observed HeLa cell culture 
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Figure 4.11: Internalization of PEGilated albumin nano-CLPA observed NIH3T3 cell 
culture 
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There has been precedence that in coating of nano-particles with amine functionalized 
PEG, polymer chain length hasn’t significantly affected the internalization behavior53. 
Nevertheless, parameters such as polymer chain length, and charge effect of functional 
groups on the surface and density of surface modification, must be further analyzed. These 
initial observations lead to conclude, that modification of nano-CLPA surface could be a 
plausible way to obtain desired internalization trend or otherwise, where necessary for a 
certain application, prevent internalization.    
 
Homogenization medium 
It has been initially suspected that particle shape and mechanical behavior may be the 
responsible parameters governing internalization. No evidence to this assumption has been 
observed throughout the results, including internalization of PEGilated nano-particles 
presented above.  
 
Parameter suspected to effect the particle shape, namely homogenization medium, has been 
utilized here, furthermore presenting evidence rejecting the initial assumption. No 
detectable difference could be observed upon internalization of different protocol albumin 
alpha-galactosidase nano-CLPA (Figure 4.12) 
 
 
 
 
 
 
 
122 
 
 
a) albumin nano-CLPA internalization 
 
b) alpha-galactosidase nano-CLPA internalization 
Figure 4.12: Internalization of nano-CLPAupon homogenization in glycerol (left) and 
ethanol (right). HeLa cell culture 
 
 
4.4.2.3.  Cell viability upon nano-CLPA internalization as a function of 
particle concentration 
 
Cell viability upon nano-CLPA internalization has been additionally assessed on HCT116, 
HEK293 and NIH3T3 cell lines, afforded by MTT cell viability assay. 
Particle concentration dependant cell viability upon 3 hour incubation was assessed over 
the course of 2 days, on glutaraldehyde crosslinked albumin homogenized in glycerol 
medium and dextran polyaldehyde alpha-galactosidase nano-CLPA homogenized in 
absolute ethanol medium, to aid 400 nm particle sizes. 
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Confocal microscope imagery was obtained on additional cell cultures, upon internalization 
of the particles subsequently used for dose dependent proliferation study, in order to 
confirm that the effect is indeed related to internalization (Figures 4.13-15).   
 
 
Figure 4.13: Confocal microscope images of internalized albumin (left) and alpha-
galactosidase (centered) nano-CLPA presented against control cells (right) in HCT116 cell 
culture 
 
 
Figure 4.14: Confocal microscope images of internalized albumin (left) and alpha-
galactosidase (centered) nano-CLPA presented against control cells (right) in NIH/3T3 cell 
culture 
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Figure 4.15: Confocal microscope images of internalized albumin (left) and alpha-
galactosidase (centered) nano-CLPA presented against control cells (right) in HEK293 cell 
culture 
 
Upon incubation with albumin nano-CLPA, reversible increase in proliferation could be 
observed at small dosage treatment and some cytotoxicity effect was detected at higher 
doses in HeLa cell culture (Figure 4.16). Somewhat more consistent dosage dependent 
trend was observed in alpha-galactosidase nano-CLPA treated culture, with observed 
proliferative induction of 20% 0.0 µg/ml dose (Figure 4.17). 
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Figure 4.16: Dosage dependent effect of albumin nano-CLPA on HeLa cell proliferation 
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Figure 4.17: Dosage dependent effect of alpha-galactosidase nano-CLPA on HeLa cell 
proliferation 
 
The pattern observed above resembled that of HCT116 cell culture, with the difference of 
proliferation increase in small doses more pronounce upon 24 hours after nano-particle 
treatment (Figure 4.18). This difference was assigned to different metabolic activities in 
between cell cultures.  Furthermore, more pronounced cytotoxicity effect with increasing 
dosage was observed in both albumin and alpha-galactosidase nano-CLPA treatment 
(Figure 4.19) as opposed to although minor but prolonged proliferation induction of small 
doses in HeLa cell culture. 
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Figure 4.18: Dosage dependent effect of albumin nano-CLPA on HCT116 cell proliferation 
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Figure 4.19: Dosage dependent effect of alpha-galactosidase nano-CLPA on HCT116 cell 
proliferation 
   
Trials were also conducted on non cancerous cell lines, in order to further assess generality 
of effect of dosage related proliferation behavior.  
Surprisingly enough, statistically insignificant cytotoxicity was detected upon treatment 
with high doses of both albumin and alpha-galactosidase nano-CLPA of NIH/3T3, as 
opposed to cancer cell lines assessed above. Slight proliferative induction could be 
observed upon internalization with albumin nano-CLPA, particularly at concentration of 
0.1µg/ml. 
 
 
129 
 
 
Figure 4.20: Dosage dependent effect of albumin nano-CLPA on NIH/3T3 cell proliferation 
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Figure 4.21: Dosage dependent effect of alpha-galactosidase nano-CLPA on NIH/3T3 cell 
proliferation 
   
Highest proliferative induction could be detected in the case of small dosage treatment of 
HEK293 cell culture, once again most pronounce at 0.1µg/ml nano-particle concentration. 
Some cytotoxicity was observed in case of high alpha-galactosidase nano-CLPA 
concentrations.  
131 
 
 
Figure 4.22: Dosage dependent effect of albumin nano-CLPA on HEK293 cell proliferation 
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Figure 4.23: Dosage dependent effect of alpha-galactosidase nano-CLPA on HEK293 cell 
proliferation 
 
The above results show good reproducibility upon 4 independent experiment repetitions, of 
triplicated measurements. Nevertheless, since viability was only assessed by MTT assay, 
the increase in color yields in cases of small dosages observed could actually be the result 
of increased mitochondrial enzymatic activity, rather than assumed proliferation induction. 
Alternative proliferation assessment techniques must be utilized in order to verify the above 
data. 
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5. Conclusion 
 
 
 
Over the course of this study general methodology leading to crosslinked protein 
aggregates (CLPA) has been assessed on a number of proteins and optimized in detail on 
albumin, trypsin, chymotrypsin, lysozyme and hemoglobin. Furthermore, crosslinked 
protein lyophilizates (CLPL) were developed on the example of trypsin and chymotrypsin.      
Downsizing procedures were developed on the basis of the results obtained from precursor 
CLPA. The approach was utilized through mechanic and hydrodynamic shear modes. 
While successful utilization of both methods in generation of nano-particle species was 
established, hydrodynamic shear realized through homogenization was employed in further 
downsizing optimization, due to convenience and operating precision on the laboratory 
scale. Homogenization conditions, ie. homogenization medium composition, 
homogenization rate and time, along with precursor CLPA/CLPL synthesis protocol have 
formed operational parameters in conducted optimization.  
Homogenization in salt and small sugar solutions have resulted in nano-particle generation, 
but with insignificant yield of approximately 10 %. Homogenization yield issue was 
resolve by incorporation of 10-70 wt% glycerol in homogenization medium, leading to 
nanonization yields approaching 100%. Furthermore, smaller particle generation capacity 
(nanonization efficiency) and homogeneous particle distribution have been greatly 
improved. Alternatively homogenization in absolute ethanol while retaining high 
nanonization yield has provided much milder conditions, shown necessary in the case of 
less rigid CLPA/CLPL formulations. 
Homogenization rate formed the major parameter in adjusting the desired particle size, 
combined with appropriate glycerol concentration precision of 10 to 20 nm distribution 
could be achieved. Time of homogenization, on the other hand determined the quality of 
particle distribution, with at least 30 min homogenization required for glycerol medium and 
slightly reduced time of 20 min for absolute ethanol homogenizations in order to achieve 
higher quality of particle distribution homogeneity described. 
CLPA/CLPL protocol effect could be generally described as more brittle formulations 
nanosized more readily, implying rigidity of precursor aggregate formation and higher 
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crosslinking degree. That being said, successful nanonizaton was achieved for all optimized 
CLPA/CLPL formulations through appropriate adjustment of homogenization parameters, 
with an exception of dehydrothermally crosslinked lyophilizates.  
Finally, potential biomedical applications have been suggested on the example of 
hemoglobin, lysozyme and complex CLPA of the resultant co-aggregation. Preliminary in 
vitro studies have been performed on the model of albumin and alpha-galactosidase nano-
CLPA. Successful internalization was demonstrated on particles of 200 nm and larger. No 
internalization occurred upon incubation with 100 nm particles. Internalization rapidly 
occurred within 30 min of incubation increasing with prolonged incubation times. Pegilated 
nano-particle appeared to modify internalization efficiency, and can be further explored as 
a parameter in achieving desired nano-particle - cell interaction. Viability assay showed 
some cytotoxicity upon treatment with higher nano-particle doses (in general 10-100 µg/ml 
final concentration in the medium) dependant on cell culture involved. Higher cytotoxicity 
was observed in HeLa and HCT116 cultures, as compared to NIH/3T3 and HEK293 
cultures. Some increase in cell proliferation was observed at low dose treatments (0.01-0.1 
µg/ml) in some cases. 
Much more extended studies are required to quantitatively assess the results, but this initial 
work provides an overview of nano-CLPA behavior. 
It can be concluded that development of successful alternative to conventional nano-scale 
immobilized protein formulation has been achieved. The main benefit of the developed 
method is convenience and rapid synthesis mode of nano-particle generation. General 
applicability of the method has been demonstrated and can be further readily applied to 
desired protein type formulations. 
The main focus of the future work involves analysis of detailed heterogeneous catalyst 
systems on the model of nano-CLPA, targeting to form a better understanding of the 
theoretical basis of kinetic and reaction limitations in the particle as a function of protocol 
and particle size.  Particularly, construction of a working model for Michaelis-Menten 
enzyme kinetics under heterogeneous reaction conditions at fixed size distribution, thereby 
establishing the threshold size of the particle and substrate to avoid diffusion control and to 
ensure reaction control.  
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